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Abstract
DNA double strand breaks represent the most toxic form of DNA damage. In mammals, nonhomologous end-joining (NHEJ) is the primary DNA repair pathway for such damage,
preventing both carcinogenesis and accelerated aging. Structural understanding of this repair
pathway has received considerable attention, but has been significantly limited by the
inability to obtain structures of higher order nucleoprotein complexes. A main obstacle in this
respect has been difficulty in obtaining highly purified proteins, sufficient for structural
determination. Improved protein expression and purification methods developed in this thesis
permitted several NHEJ complexes to be selected for structural studies. Among these, Ku70DNA and Ku70-DNA-PAXX yielded promising preliminary results. In depth optimization
for crystal growth was performed and resulted in a full-length PAXX homodimer structure as
well as low-resolution diffraction data for a novel Ku70-DNA complex. The PAXX structure
confirmed prior suggestions that the C-terminal region of PAXX is highly disordered.

Keywords
DNA double strand breaks, Ku70, Non-homologous end joining, PAXX, Protein expression,
Protein purification, Protein structure, X-ray crystallography

ii

Acknowledgments
I owe my utmost gratitude to Dr Murray Junop for granting me the opportunity to explore
one of the most vital mechanism for genome integrity. Dr Junop has been a wonderful
supervisor, an irreplaceable mentor, provided me with insights into research and aspects of
life, all the while tolerating my peculiar sense of humour, and without whom this thesis
simply would not be possible. My committee advisors Dr Brian Shilton and Dr Hong Ling’s
expert opinions, and for offering me much needed guidance to shape my research direction.
The kindness and refreshing advices from Drs David Litchfield, Derek McLachlin and
Caroline Schild-Poulter were very much appreciated as they accompanied my learning
experiences. I thank Dr Alba Guarné and Jeremy Caron for inspiring the crystallographer in
me, Dr Mac Mok and soon-to-be Drs Robert Szabla for software assistance in data
processing, Chris Brown and Sam Chu for technical assistance in experiments, and the rest of
the Junop lab for the brainstorming and cheerful banters, and all aforementioned profusely
for allowing me to tap into your wisdom and expertise.
I would also like to thank my family; Western’s varsity fencing team, Carol, Brad, and
teammates, whose love and support brought me constant joy and strength; teammates and
classmates from McMaster University, Bayview Secondary and Walter Murray Collegiate,
always there for me through the high and lows. M.Sc. has been a challenging journey, but
among the stress and struggles rise a realistic sense of self-efficacy, and skills that are only
earned after enormous efforts.

iii

Table of Contents
Abstract ............................................................................................................................... ii
Acknowledgments.............................................................................................................. iii
Table of Contents ............................................................................................................... iv
List of Tables .................................................................................................................... vii
List of Figures .................................................................................................................. viii
List of Appendices .............................................................................................................. x
Abbreviations ..................................................................................................................... xi
Chapter 1 ............................................................................................................................. 1
1 Introduction .................................................................................................................... 1
1.1 DNA Double Strand Breaks.................................................................................... 1
1.2 DNA Double Strand Break Repair Pathways ......................................................... 4
1.2.1

Homologous Recombination ...................................................................... 6

1.2.2

Classical Non-Homologous End Joining .................................................... 6

1.2.3

Alternative Non-Homologous End Joining .............................................. 11

1.3 NHEJ Core Factors ............................................................................................... 11
1.3.1

DNA Ligase IV ......................................................................................... 11

1.3.2

XRCC4...................................................................................................... 14

1.3.3

XLF ........................................................................................................... 17

1.3.4

Ku70/80..................................................................................................... 18

1.3.5

PAXX........................................................................................................ 24

1.4 Thesis Objectives .................................................................................................. 25
Chapter 2 ........................................................................................................................... 26
2 Methods ........................................................................................................................ 26
2.1 Plasmid Constructs................................................................................................ 26
iv

2.2 Protein Expression and Purification...................................................................... 27
2.2.1

DNA Ligase IV/XRCC4 (LX4) ................................................................ 27

2.2.2

XLF ........................................................................................................... 28

2.2.3

Ku70/80..................................................................................................... 28

2.2.4

Ku70 .......................................................................................................... 29

2.2.5

PAXX........................................................................................................ 30

2.3 Protein Quantification ........................................................................................... 31
2.4 SDS-PAGE ........................................................................................................... 31
2.5 Western Blot ......................................................................................................... 31
2.6 SEC-MALS Analysis ............................................................................................ 32
2.7 DNA Ligation Assay............................................................................................. 32
2.8 DNA Substrates for Crystallography .................................................................... 33
2.9 Electrophoretic Mobility Shift Assay ................................................................... 34
2.10 Crystallography .................................................................................................... 34
2.10.1 Crystallization of LX4, LX4-DNA, LX4-XLF-DNA ............................... 35
2.10.2 Crystallization of Ku70, Ku70-DNA, Ku70-DNA-PAXX ....................... 35
2.10.3 Optimization of Ku70-DNA and Ku70-DNA-PAXX Crystals ................ 36
2.11 X-ray Diffraction Data Collection ....................................................................... 36
2.12 Structural Determination and Refinement ........................................................... 37
Chapter 3 ........................................................................................................................... 38
3 Results .......................................................................................................................... 38
3.1 Improvements in Production of NHEJ Factors ..................................................... 38
3.1.1

Purification of LX4, XLF and Ku70/80 .................................................... 38

3.1.2

Purification of Ku70 and PAXX ............................................................... 45

3.2 Purified LX4 Retains Ligation Activity................................................................ 49
3.3 Ku70 Forms a Stable Dimer in Solution ............................................................... 51
v

3.4 Ku70 Homodimer Exhibits DNA Binding Activity ............................................. 53
3.5 Crystallization Screening of LX4, LX4-DNA and LX4-XLF-DNA .................... 55
3.6 Crystallization of Ku70 and Ku70-DNA .............................................................. 58
3.7 Optimization of Ku70-DNA Crystals Improved Diffraction Data Quality .......... 63
3.8 Crystallization of Ku70-DNA-PAXX Generated PAXX Crystals ....................... 67
3.9 PAXX Structure Determined from Full-length PAXX......................................... 71
Chapter 4 ........................................................................................................................... 73
4 Discussion .................................................................................................................... 73
4.1 Overcoming Practical Limits to Studying NHEJ Complex Structures ................. 74
4.2 Crystallographic Strategies to Facilitate High Quality Diffraction Data .............. 76
4.3 Methods to Complement Crystal Structure Determination .................................. 79
4.4 Implications for NHEJ Complex Interactions....................................................... 80
4.5 Outstanding Questions for NHEJ in Cancer Treatment ........................................ 82
References ......................................................................................................................... 83
Appendices ...................................................................................................................... 100
Curriculum Vitae ............................................................................................................ 113

vi

List of Tables
Table 1. Comparison of prokaryotic and eukaryotic NHEJ homologs ..................................... 9
Table 2. Summary of purification yield of NHEJ factors ....................................................... 48
Table 3. Components of promising Ku70-DNA crystallization conditions ........................... 62
Table 4. Optimization of MCSG I #95 for Ku70-loop16 ....................................................... 66
Table 5. Comparison of Ku70-DNA and Ku70/80-DNA crystal parameters ......................... 66
Table 6. Summary of PAXX Crystallization and X-ray diffraction ....................................... 69
Table 7. Comparison of experimental and referenced PAXX crystal parameters .................. 70

vii

List of Figures
Figure 1. Overview of the causes and response of DNA double strand breaks ........................ 3
Figure 2. Overview of DNA repair pathway preference........................................................... 5
Figure 3. Overview of NHEJ general mechanism and complex assembly ............................. 10
Figure 4. Structure of DNA Ligase IV catalytic domain in complex with an Artemis peptide
................................................................................................................................................. 13
Figure 5. Crystal structures of XLF and XRCC4-DNA Ligase IVBRCT.................................. 15
Figure 6. Filament assembly of XRCC4 and XLF ................................................................. 16
Figure 7. Domains of Ku70 and Ku80 .................................................................................... 22
Figure 8. Crystal structure of Ku70/80 ................................................................................... 23
Figure 9. Representative purification of LX4 complex .......................................................... 40
Figure 10. Purification of XLF ............................................................................................... 42
Figure 11. Ku70/80 Autoinduction profile ............................................................................. 43
Figure 12. Purification of Ku70/80 ......................................................................................... 44
Figure 13. Purification of Ku70 .............................................................................................. 46
Figure 14. Purification of PAXX ............................................................................................ 47
Figure 15. DNA ligation assay showing LX4 activity............................................................ 50
Figure 16. SEC-MALS data showing stable dimer of Ku70 in solution ................................ 52
Figure 17. Analysis of Ku70 DNA binding activity with loop16 DNA substrate .................. 54
Figure 18. Unoptimized LX4 crystals ..................................................................................... 57
viii

Figure 19. Typical Ku70 non-diffracting microcrystals ......................................................... 60
Figure 20. Initial hits of Ku70-DNA crystals ......................................................................... 60
Figure 21. DNA crystals obtained from Ku70-DNA complex crystallization ....................... 61
Figure 22. Diffraction patterns of the initial hits of Ku70-DNA ............................................ 61
Figure 23. Progression of Ku70-loop16 crystal morphology through iterations of
optimization ............................................................................................................................ 65
Figure 24. Progression of Ku70-DNA crystal X-ray diffraction data quality ........................ 65
Figure 25. Initial hit of Ku70-DNA-PAXX complex ............................................................. 68
Figure 26. Images of PAXX crystals in two different crystallization conditions ................... 68
Figure 27. Single image of X-ray diffraction pattern from PAXX data collection ................ 70
Figure 28. Highlighted Structural Information of PAXX ....................................................... 72
Figure 29. Idealized states of solutes ...................................................................................... 78

ix

List of Appendices
Appendix 1. List of oligonucleotides .................................................................................... 100
Appendix 2. Structure of annealed DNA substrates ............................................................. 102
Appendix 3. Comparison of XLF expression and purification using different methods ...... 106
Appendix 4. Ku70-DNA bound in solution .......................................................................... 107
Appendix 5. List of crystallization conditions for Ku70 and X-ray screening outcomes..... 108
Appendix 6. List of crystallization conditions for Ku70-DNA and X-ray screening outcomes
............................................................................................................................................... 109
Appendix 7. Optimization of Wizard I #10 and MCSG II #80 for Ku70-loop16 crystal
growth and X-ray diffraction ................................................................................................ 111
Appendix 8. Ku70-DNA, Ku70-DNA-PAXX crystallization conditions ............................ 112

x

Abbreviations
5’dRP/AP site 5' deoxyribosephosphate / apurinic and apyrimidinic site
53BP1 p53 binding protein 1
a-NHEJ alternative Non-Homologous End Joining
AP apurinic/apyrimidinic
APS Advanced Photon Source
ATM ataxia telangiectasia mutated
ATR ataxia telangiectasia and Rad3 related
Bax B-cell lymphoma 2 associated X
bp base pair
BRCT breast cancer 1 C Terminus
c-NHEJ classical Non-Homologous End Joining
CDK cyclin dependent kinase
CHK1 checkpoint kinase 1
CHK2 checkpoint kinase 2
Cryo-EM cryo-electron microscopy
CtIP C-terminus binding protein interacting protein
cv column volume
DNA-PKcs DNA-dependent protein kinase catalytic subunit
DSB double strand break
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EtBr ethidium bromide
H2AX histone H2A, member X
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
IPTG isopropyl β -D-1-thiogalactopyranoside
Ku70/80 Ku70 / Ku80 heterodimer
LB Lysogenic Broth-Lennox
LX4 DNA Ligase IV / XRCC4 complex
MRN Mre11, Rad50, and Nbs1 complex
Ni column Ni2+ charged immobilized metal affinity column
xi

NLS nuclear localization signal
NMR nuclear magnetic resonance spectroscopy
PARP1 Poly [ADP-ribose] polymerase 1
PAXX Paralog of XRCC4 and XLF
PBS phosphate buffered saline
PEG polyethylene glycol
PIKK phosphoinositide 3-kinase-related kinase
PMSF phenylmethylsulphonyl fluoride
PVDF polyvinylidene difluoride
RAG recombination activating gene
RbCl rubidium chloride
RPA replication protein A
SAP domain SAF-A/B, Acinus and PIAS domain
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
TBS-T Tris buffered saline with Tween-20
TCEP Tris(2-carboxyethyl)phosphine hydrochloride
V(D)J Variable, Diversity and Joining
vWA von Willebrand A
XLF XRCC4-like factor
XRCC4 X-ray Repair Cross-Complementing protein 4

xii

1

Chapter 1

1

Introduction

Failure to properly repair DNA damage affects both cancer formation and treatment. In
normal cells, the lack of timely DNA repair leads to genomic instability and is considered
one of the most important hallmarks of cancer development. Conversely, the increased
DNA damage resistance in cancer cells in response to chemotherapeutic agents often
originates from upregulated DNA repair genes (1). Such altered physiology of cancer
cells opens the potential for new strategies of cancer treatment, which typically utilize
DNA damaging agents to exploit the elevated levels of replication in cancerous cells.
Conventional radio- and chemotherapy causes indiscriminate DNA damage to all cells in
the body, although preference to killing is directed towards cancerous cells due to their
rapidly dividing nature. In tumours that have undergone relapse, the upregulated DNA
repair capacity of cancer cells decreases the effectiveness of further DNA damaging
chemotherapeutics. Continued treatment has a negative effect on patient well-being, and
leads to heightened mutation rates and further resistance toward therapy. Thus, targeting
the prominent DNA repair pathway in tumour cells provides an effective way of resensitizing tumours to DNA damaging radio- and chemotherapies (2). Understanding the
mechanisms of DNA repair assists such effort by providing necessary insight for
development of small molecules that modulate cellular responses to DNA damage.
This chapter delineates the current research in the field of DNA damage and repair
pathways, with a focus towards the structures and mechanisms of DNA double strand
breaks, repair, and interactions of repair factors.

1.1 DNA Double Strand Breaks
Genome stability constitutes a crucial aspect safeguarding human health and longevity.
Our genome is constantly bombarded by DNA damaging events, including those
resulting from ordinary cell processes (3). Ionizing radiation and other clastogenic agents,
frequently used in cancer treatments, generate DNA damage (4). Of these, perhaps the
best studied is ionizing radiation. Due to the heterogeneity in energy deposition, ionizing
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radiation creates pockets of radicals in the aqueous environment of a cell, either through
direct ionization of DNA molecules (5) or formation of hydroxyl radicals, that
subsequently react with and damage DNA (6–8). This results in a complex variety of
types of damage to the DNA, including single- and double-strand breaks, base and
deoxyribose damage, and DNA-protein crosslinks (9, 10). In addition to exogenous
sources of damage, cellular respiration also generates reactive oxygen species as a side
product of the electron transport chain, and damages DNA in a similar manner (11, 12).
DNA double strand breaks occur when single-strand breaks are generated on
complementary strands of a DNA helix within close distance (~10 base pairs, bp). In
dividing primary mammalian fibroblasts, it is estimated that DSBs occur at a rate of
about ten per day per cell (13, 14). Such damage can result in small local alterations to
DNA sequence as well as larger chromosomal loss or rearrangements if the broken DNA
ends fail to remain in close proximity for repair (Figure 1).
Due to the severity of such damage, even a single unrepaired DSB can lead to replication
arrest and cell death (15). When a substantial number of cells experience senescence or
apoptosis due to extensive DNA damage, it can lead to tissue atrophy resulting in
eventual organ failure. DNA repair mechanisms are also involved in telomere
maintenance, and failure in these two cell functions mirrors effects of accelerated aging
(16–18). Indeed, the frequency of chromosome aberrations increases with age, suggesting
that the rate of aging is related to DNA repair capacity (19). Equally undesirable, misrepaired DSBs cause chromosomal mutations including sequence alterations, large scale
deletions and inappropriate joining of DNA ends, resulting in further genomic instability
through loss of tumour suppressor genes or activation of oncogenes. Ensuring an
effective DNA repair system is a fundamental condition for human survival. Thus, efforts
to understand DNA repair mechanisms are crucial for gaining insight to understand the
basis for its failure, and ultimately formulate ways to modulate the repair process for
improved cancer treatments.
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Figure 1. Overview of the causes and response of DNA double strand breaks. The
blue arrow denotes parallel responses; orange arrows lead to outcomes when the repair
fails; the green arrow leads to successful repair. Adapted from (18).
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1.2 DNA Double Strand Break Repair Pathways
DNA repair provides the path for all organisms to maintain genome stability against a
plethora of damaging agents. The two major DSB repair pathways in mammals are
homologous recombination (HR) and non-homologous end joining (NHEJ). Within
NHEJ, there is a classical NHEJ (c-NHEJ) pathway and alternative NHEJ (a-NHEJ)
pathway also known as microhomology mediated end joining. Suppressed by c-NHEJ
under normal circumstances, the a-NHEJ pathway acts as a backup when c-NHEJ fails
and HR is unavailable or also fails (20). Both HR and c-NHEJ have additional roles in
normal cell processes. HR is responsible for generating genetic diversity during meiosis
of gamete cells (21) while NHEJ factors are employed in V(D)J recombination integral to
the adaptive immune system through T and B cell maturation (22). The prioritization and
choice of different pathways for repair is related to their efficiency and availability
(Figure 2). Despite the desirable quality of HR, which is able to maintain sequence
fidelity by using a sister chromatid or homologous chromosome as a template for repair,
HR does not constitute the major repair pathway in mammals because it is not always
available to the cell. As the only time during the cell cycle that a sister chromatid is
available, or homologous chromosomes is in close proximity to serve as a template is
during the S/G2 phase, HR presents a desirable outcome for repair at only these phases of
the cell cycle (23, 24). During the remainder of the cell cycle, c-NHEJ is the most
prominent pathway, owing to its rapid activation and ability to re-join numerous types of
DSBs (25).
The activation of DNA repair is only one component of the DNA damage response.
Following initiation of repair, a composite signalling cascade is engaged in the cell
directing its fate. DNA damage “sensors”, phosphatidylinositol 3-kinase-related kinases
(PIKK) including ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and
Rad3 related (ATR), interact with DSB DNA ends and mediates the repair pathways by
interacting with a Mre11, Rad50 and Nbs1 (MRN) complex or DNA-PKcs (26–28). They
also control cell cycle checkpoints by signalling through Chk1 and Chk2 (29, 30). Upon
DNA damage, the histone H2AX is phosphorylated on serine 139 by ATM, allowing the
chromosome to become less condensed, thereby facilitating access by DNA repair
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Figure 2. Overview of DNA repair pathway preference. Ku70/80, with its high
abundance and affinity for DNA ends, is typically the first to interact with the DNA ends,
initiating the c-NHEJ pathway. Failing this, HR elements binds ends and the HR pathway
proceeds. If NHEJ and/or HR are unable to repair the DNA damage in a timely manner,
a-NHEJ pathway may be used as a final means to avoid chromosome loss or
translocation.
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factors. ATM also phosphorylates tumour suppressors, such as p53, whose activation
occurs when DNA damage is beyond repair (31, 32). Under such conditions, p53 acts as a
transcription factor for expression of proapoptotic proteins including B-cell lymphoma 2
associated X protein (Bax), and activates the mitochondrial pathway for programmed cell
death (33). The elaborate process of DNA damage response is a field of active research,
and a full description can be found in recent reviews (32, 34, 35).

1.2.1

Homologous Recombination

HR conserves genetic information by utilizing an undamaged DNA template,
preferentially the sister chromatid, for repair (36). Because of the need for a sister
chromatid or homologous chromosome to be in physical proximity to a DSB for
complementary base pairing with the broken DNA strand, HR occurs more readily during
the S and G2 phases of the cell cycle when homologous templates are accessible. During
repair by HR, an MRN complex binds to the DNA at the double strand break and tethers
the two ends in close proximity. C-terminus binding protein interacting protein (CtIP)
binds the MRN complex and initiates DNA resection of the 5’ strands, leaving 3’ singlestranded DNA tails protected by Replication Protein A (RPA). Further resection is
carried out by downstream factors. Radiation Sensitive 51 (RAD51) displaces RPA and
forms filaments on the single-stranded DNA, promoting homologous pairing and strand
invasion (37). Following DNA synthesis, the two DSB ends align with their respective
homologous strand forming a double Holliday junction, which is then resolved by
resolvase enzymes. In meiotic DSB repair, crossover products are generated allowing
genetic exchange. In mitotic DSB repair, the DSB site is joined in a non-crossover
manner to preserve the template sequence (38).

1.2.2

Classical Non-Homologous End Joining

Despite HR providing potential for high-fidelity repair during late S phase and G2 phase,
NHEJ is the prevalent pathway employed to repair DSB in mammalian cells. Although
NHEJ is error prone, the ability to rapidly ensure chromosomes remain intact supersedes
the negative consequences of local mutations at the breakage site which are frequently
acquired during repair. With a lack of homology based, “proofing template” for repair,
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the process of NHEJ relies critically on its fast kinetics to minimize the consequences of
DSB damage and mend the ends through ligation (39–41).
Two types of NHEJ exist, with c-NHEJ being the dominant pathway due to its rapid
ability to re-join DNA ends thereby protecting from large resection or involvement in
DNA rearrangement. As a vital repair mechanism for DNA DSB repair in mammalian
cells, c-NHEJ employs a small set of core factors with impressive versatility in
recognizing and processing DNA ends for efficient end joining. Depending on the
complexity of the damaged DNA ends, the rate of c-NHEJ can be three to six times
higher than HR (25). The core factors involved in c-NHEJ have been identified.
Numerous auxiliary factors, including nucleases and polymerases, are also recruited to
the damage site as needed to facilitate the repair process (42). While the primary
sequence of NHEJ repair factors are poorly conserved, functional homologs of the core
factors can be found widely across evolutionary descendants (Table 1).
The c-NHEJ pathway consists of three main steps: synapsis, end processing, and end
joining (48) (Figure 3). When a DSB event occurs, the Ku70/80 heterodimer binds to
each of the two DSB ends within seconds (39). Ku70/80 is constitutively expressed, and
is one of the most abundant proteins in the cell. Its ring-shaped structure allows it to
thread onto the broken DNA end in a sequence independent manner (49). In doing so, Ku
also excludes HR from occurring by sterically blocking DNA resection factors required
for HR (50). Following end binding, Ku70/80 translocates inward on the DNA for about
one helical turn distal from the free end, allowing for recruitment of DNA-dependent
protein kinase catalytic subunit (DNA-PKcs). DNA-PKcs directly interacts with DNA
and occupies a region of ~10 bp proximal to the free end (51). Together, Ku70/80 and
DNA-PKcs make up the DNA-dependent protein kinase holoenzyme (DNA-PK) which is
able to synapse the two broken DNA ends, preventing them from long-range movements
that would make re-joining of ends very challenging (52, 53). Interestingly, DNA-PKcs
has only been identified in eukaryotes (54–56). NHEJ in prokaryotes require only a
homodimer of Ku in complex with LigD, a DNA Ligase IV homolog (57, 58). This
implies that Ku70/80 may be sufficient for simple end joining, and that DNA-PKcs
represents a more elaborate, evolutionarily recent mechanism to manage complex aspects

8

of DNA repair such as cell cycle regulation. Phosphorylation by DNA-PK provides the
means by which many interacting factors are recruited and regulated during repair. The
dissociation of DNA-PK from the damage site after repair completion is suggested to
depend on the auto-phosphorylation of DNA-PKcs, further indicating its function in
coordinating the repair complex (59).
Due to the frequent presence of complex types of damage at a DSB, end processing
represents an important part of DSB repair by NHEJ. The ability to accommodate diverse
types of DNA ends underscores the multifunctionality and mechanistic flexibility of
repair factors involved in end processing. In simple end joining, Ku70/80 has the capacity
to coordinate ligation with downstream factors independent of DNA-PKcs (60). Cryoelectron microscopy (cryo-EM) and small angle X-ray scattering (SAXS) data have
provided some insight into the assembly, auto-phosphorylation, and disassembly stages
of DNA-PKcs activity (61–63). DNA-PK orchestrates an array of nucleases including
Artemis, which is phosphorylated by DNA-PKcs, enabling its endonucleolytic activity
(64, 65). Polymerases including polμ and polλ are also recruited to adaptively modify
DNA ends to make them chemically compatible for ligation (66, 67).
Finally, ligation of DNA is carried out by a ligase complex comprised of DNA Ligase IV,
X-ray cross-complementation group 4 (XRCC4) and XRCC4-like factor/Cernunnos
(XLF) (68–70). This ligation complex has been shown to be able to join DNA ends with
blunt, microhomology, and non-compatible sequences. With coordinated positioning of
DNA ends (termed DNA bridging) by filaments of XRCC4/XLF, DNA Ligase IV is
stabilized at ends to form a covalent AMP-enzyme intermediate on a highly-conserved
lysine residue (K273). This AMP is subsequently transferred to the 5’ phosphate group of
a DNA end. Following SN2 substitution by an activated 3’ hydroxyl group from the
opposing strand, with AMP as the leaving group, the sugar phosphate backbone of DNA
is re-joined.
It is important to note that NHEJ does not proceed in an absolute step-wise fashion.
Ku70/80 directly interacts with many factors including DNA-PKcs (71), XRCC4 (39),
DNA Ligase IV (72), XLF (73), and a paralog of XRCC4 and XLF (PAXX) (74), and it
is not yet clear how these various assemblies contribute at different stages of repair.
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Table 1. Comparison of prokaryotic and eukaryotic NHEJ homologs. Core factors in
NHEJ are functionally conserved.

Prokaryote (43)
Eukaryote:
Saccharomyces
cerevisiae (44–46)
Human (47)

End recognition

End processing

Ligase

Ku (30-40kDa)

LigD

LigD

Ku70/80

pol4

Ku70/80

polµ and polλ,
Artemis

Lif1 + Dnl4 + Nej1
XRCC4 + DNA
Ligase IV + XLF
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Figure 3. Overview of NHEJ general mechanism and complex assembly. Ku70 (red)
and Ku80 (yellow) form the heterodimer that detects an initial DSB break. Ku80 contains
a C-terminal DNA-PKcs interaction domain that recruits DNA-PKcs (blue), forming a
DNA-PK holoenzyme. The incompatible DNA ends (red) are modified by various end
processing factors to make them compatible for ligation (green). XLF (grey), XRCC4
(olive) and DNA Ligase IV (brown) form a ligation complex at the DNA terminus in a
filamentous arrangement that stabilize the ends for efficient ligation.
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1.2.3 Alternative Non-Homologous End Joining
In the event that both c-NHEJ and HR fail, the a-NHEJ pathway may complete repair
though a mechanism that requires end-to-end stabilization provided by the presence of
micro-homology at opposing ends of the DSB. Given the serious nature of failure to
repair a DSB, it is not surprising that cells have a backup repair mechanism to restore
chromosome integrity and prevent chromosome loss (75, 76). Both c-NHEJ and HR
factors have been suggested to participate in the a-NHEJ pathway (77, 78), thus
recruitment of repair factors in a-NHEJ may be a function of their presence during the
initial repair attempt. In cells with deficient Ku heterodimer, a-NHEJ is significantly
elevated, which was initially termed Ku-independent pathway (20, 79). A-NHEJ is errorprone as it relies on only a few bases of homology at the broken DNA ends to promote
stability. These sites of micro-homology typically form after small amounts of 5’ strand
resection. Repair by a-NHEJ occurs with slower kinetics and is implicated in
chromosome translocation events contributing to cancer (75, 80). End joining in a-NHEJ
is dependent on both Poly [ADP-ribose] polymerase 1 (PARP1) and DNA Ligase III
(79). This pathway was only recently identified and has not been well studied. It will be
interesting to see what redundancies, if any, exist between a-NHEJ and c-NHEJ.

1.3 NHEJ Core Factors
1.3.1 DNA Ligase IV
DNA Ligase IV has been identified as the crucial ligase component in joining ends at a
DSB, and its function appears to be limited to c-NHEJ. Not surprisingly, a DNA Ligase
IV knockout results in complete abolishment of c-NHEJ repair capacity, causing severe
radiosensitivity and immunodeficiency in patients (81–84). In the absence of DNA
Ligase IV, cells are forced to attempt repair through the less available HR or error-prone
a-NHEJ. The error-prone repair of a-NHEJ may lead to chromosome translocation as
utilizing micro-homology has potential to direct the damaged end to the end of other
chromosomes. When DNA Ligase IV is utilized as part of the c-NHEJ pathway,
translocation rates are shown to suppressed (85).
On its own, DNA Ligase IV is very unstable and undetectable in cells. It is stabilized
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through formation of a DNA Ligase IV-XRCC4 (LX4) complex, as shown in both
mammal and yeast cells (86, 87). Deletion and/or mutation of genes for either XRCC4 or
Ligase IV both result in similar phenotypes including severe combined
immunodeficiency (SCID), hypersensitivity to DSB formation, neuronal apoptosis and, in
the case of a complete gene deletion, embryonic lethality (88).
The structure of full length Ligase IV has not been determined, although the catalytic
region of the protein (including the nucleotidyltransferase domain and an OB-fold
domain) in complex with an Artemis polypeptide has been solved by X-ray
crystallography (PDB 3W1G, Figure 4) (89, 90). The C-terminal domain of Ligase IV is
required for interaction with XRCC4 and its recruitment to sites of DNA damage (91).
The interaction of Ligase IV with XRCC4 maps to the two breast cancer associated 1 C
Terminus (BRCT) domain at the C-terminus of Ligase IV, and the C-terminal tails
(residues 160-200) of XRCC4 homodimer (89, 92). The binding results in a 1:2
stoichiometry and is therefore asymmetric in nature. Due to its similarity in domain
organization with DNA Ligase I and III, its interaction with DNA is anticipated to occur
in a similar manner. Ligase I and III have been shown to bind DNA by encircling DNA
with the DNA binding domain, nucleotidyltransferase domain, and OB-fold domain (93,
94). However, this has yet to be validated through structural determination for Ligase IV.
Current knowledge on DSB repair has focused on the first strand ligation event, and
nothing is yet known about the interactions allowing a second end joining event required
to fully complete repair. Current evidence suggests that a single complex of LX4 may
seal both strands. This would require dramatic repositioning of the LX4 complex as well
as recharging Ligase IV with ATP. XLF has been shown to promote re-adenylation of
Ligase IV after the first joining event and may therefore enable the second strand to be
joined (70). It is also possible that a symmetrical LX4 complex (2:4 ratio of Ligase IV to
XRCC4) with opposing LX4 complexes on both strands, may perform ligation with each
LX4 sealing just one strand. Interestingly, there is evidence to suggest that Ligase III,
typically involved in single-strand break repair, may seal the second strand following
LX4 sealing of the first strand (95). Improvement in the current understanding of the
Ligase IV mechanism will require structures of Ligase IV complexes formed with DNA
and other repair factors such as Ku70/80 and XLF.
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Figure 4. Structure of DNA Ligase IV catalytic domain in complex with an Artemis
peptide. The DNA Ligase IV catalytic domain is shown in gold, and the Artemis peptide
in cyan. The N- and C-terminus of the DNA Ligase IV catalytic domain, the Artemis
peptide, and ATP are indicated by labelled arrows of corresponding colour. The ATP
molecule (red) can be seen interacting within the catalytic domain at the location of the
catalytic lysine K273. This structure shows an open conformation in which DNA is not
bound. The structure is rendered from PDB 3W1G using PyMOL.
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1.3.2 XRCC4
DNA Ligase IV stability absolutely requires XRCC4 binding, and the crystal structure of
XRCC4 (residues 1-203) in complex with the tandem BRCT repeat region of Ligase IV
has been determined (PDB 3II6, Figure 5B). Unfortunately, this complex lacked DNA
and the catalytic core of Ligase IV (spanning the first ~600 residues). Nevertheless,
insight into LX4 complex formation was obtained and new co-expression approaches
were developed for production of the truncated complex. Utilizing a bacterial coexpression system for truncated XRCC4 and Ligase IV was essential to achieve sufficient
material for structural studies (86). Based on this success, a similar approach may prove
equally useful for structural studies of the full-length complex.
Since the reliance of DNA Ligase IV on XRCC4 for stabilization is not mutual, and there
is an excess of XRCC4 in the cell relative to Ligase IV, it is thought that excess XRCC4
is used to form filaments with XLF. Long filaments of XRCC4-XLF have been observed
in cells at DSB sites and there is evidence to suggest that Ligase IV is incorporated
throughout the entire length of the filament. XRCC4-XLF filaments move along the
DNA damaged ends, not only stably bridging ends but also positioning Ligase IV at
DNA termini for successful ligation (96, 97).
Despite their structural similarity, XRCC4 and XLF carry out distinct functions during
NHEJ repair. Functioning as a homodimer, XRCC4 associates with and is recruited to
damage sites by a homodimer of XLF. This interaction can occur without coordination of
DNA-PKcs (98), and stimulates the ligation and adenylation activity of Ligase IV by
stabilizing the complex at the DSB site (99, 100). It is currently unclear how the repair
complex manages to coordinate DNA Ligase IV to feed broken ends into its active site,
but a model for XRCC4-XLF interaction suggests a sleeve of multiple XRCC4-XLF
filaments bridges DNA ends and can accommodate necessary structural changes to
permit access of Ligase IV to DNA ends. Filament structures of XRCC4 and XLF have
been determined by X-ray crystallography (Figure 6, PDB 3SR2).
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Figure 5. Crystal structures of XLF and XRCC4-DNA Ligase IVBRCT. (A) XLF (PDB
2R9A) and (B) XRCC4-DNA Ligase IVBRCT (PDB 3II6). XLF monomers (residues 1224) within the homodimer are shown in different shades of blue. XRCC4 monomers
(residues 1-203) are in different shades of green and the tandem BRCT domain of DNA
Ligase IV are shown in red. N- and C-termini are indicated. The figure was generated
using PyMOL.

16

Figure 6. Filament assembly of XRCC4 and XLF. (A) shows the N-terminal head-tohead interaction between XRCC4 (purple) and XLF (green). (B) illustrates a single
filament formation along DNA (yellow). (C) illustrates multiple filament assembled into
a bundle, each filament in a different colour.

17

1.3.3 XLF
Relative to Ku70/80, DNA-PKcs, and LX4, XLF was only recently identified as a
necessary component for c-NHEJ and V(D)J recombination (101). XLF and its yeast
homolog Nej1 are required for successful completion of ligation, although the precise
mechanism of action remains unclear (69, 102–104). Patients with XLF-disrupting
mutations suffer an inability to complete DNA ligation at similar levels compared to
knockouts of Ligase IV and/or XRCC4, suggesting XLF interaction with these
components is necessary for successful end joining (69). XLF and XRCC4 have different
functions despite their structural homology. Functional studies show while XLF
interaction is dispensable in joining of compatible ends, the efficiency of joining
mismatched and blunt ends is largely dependent on the presence of XLF (104).
Additionally, the DNA damage response protein ATM and histone remodelling protein
H2AX share functional redundancy with XLF but not XRCC4, underscoring distinct
roles for XLF and XRCC4 (105).
Although both XLF and XRCC4 form stable homodimers in solution, their ability to
interact does not occur through heterodimer formation (106, 107). The crystal structure of
the N-terminal domain of XLF (PDB 2R9A) illustrates a crucial difference between XLF
and XRCC4. In XLF, the helical region that extends from the dimerization domain bends
back towards the N-terminal globular region, instead of continuing to extend away as a
helical coiled coil as shown in XRCC4 (Figure 5). As such, XLF exhibits a more compact
structure and precludes Ligase IV from binding in the same manner as XRCC4. Currently
there is no structure of the C-terminal region of either XLF or XRCC4. Although deletion
of this region in XRCC4 appears to be dispensable for repair, similar deletions in XLF
result in loss of DNA binding and ability to stimulate ligation of non-cohesive DNA ends
(104). In addition, deletion of the last 10 amino acids in the C-terminus of XLF (XLF 1289

) abrogates Ku70/80 interaction and results in accumulation of DSBs. This finding

underscores the essential role of the flexible C-terminus of XLF for mediating DNA and
protein-protein interaction (108). Interestingly, Ku70/80-XLF interaction appears to be
mediated by the presence of DNA, making it clear that further structural knowledge of
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the Ku70/80-XLF protein complex will be required to understand of the intricate
interactions required for successful DSB repair by c-NHEJ (108).
Interaction of XLF-XRCC4 involves association of two homodimers and has been
localized to their respective N-terminal head regions (XLF1-128 and XRCC41-119). The
resulting interaction permits further formation of an extended filament composed of
alternating XRCC4 and XLF homodimers. Single filaments further assemble into a multifilament bundle (or sleeve) that is required for stable bridging of DNA ends (68, 109–
111). Formation of multi-filament bundles is dependent on the extended tails of XLF. At
this time, it is not yet clear how the tails govern sleeve assemble or interaction with DNA.
For joining of DSBs in vitro, a ligation complex consisting of DNA Ligase IV, XRCC4
and XLF is sufficient. In cells this is not the case as Ku70/80 is required (69, 112). At
least part of this requirement is related to the ability of Ku70/80 to recruit XLF, and by
extension LX4, at the DSB site. At this time, it would appear that Ku70/80 may play a
more important role for DNA damage recognition and response, coordinating end
processing factors and repair complex regulations, rather than directly participating in
end joining.

1.3.4 Ku70/80
Ku70 and Ku80 were first discovered in 1981 as autoantigens in the serum of a
scleromyositis patient (113). Ku70/80 heterodimer is an important element of
maintaining genome stability. Its capacity to bind DNA ends is instrumental for its role in
both DNA repair and telomere maintenance. As one of the most abundant proteins in
mammalian cells, its expression is estimated at ~4×105 molecules per cell (48). As the
initial DNA damage sensor, Ku70/80 heterodimer exhibits fast kinetics in binding and
recruitment of the DNA dependent protein kinase catalytic subunit (DNA-PKcs) to form
DNA-PK holoenzyme. This kinase complex is responsible for orchestrating the
regulation of most if not all NHEJ core repair factors. Since c-NHEJ is the major DNA
repair pathway, and DNA-PK is vital for c-NHEJ, it has become a primary target for
cancer treatments aiming to knock down upregulated DNA repair in tumour cells (2).
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When multiple types of damage occurred at a DSB, a multifunctional repair factor can
provide a means for efficient repair without necessitating coordination of multiple repair
pathways. In this regard, Ku70/80 contains 5′ deoxyribosephosphate and
apurinic/apyrimidinic (5’dRP/AP) lyase activity, preferentially processing AP sites
within 1-2 nucleotides of a DSB (114). The end processing capacity of Ku70/80
resembles base repair activity observed in homodimeric Ku from prokaryotes.
Prokaryotic Ku, with its ligation partner LigD, demonstrates not only the expected DNA
end binding and joining activity (58, 115–117), but also nucleolytic activities that process
ends for efficient ligation (118).
In addition to a role in NHEJ, Ku70/80 also participates in telomere maintenance as a part
of the telomere binding complex, and is required for the perinuclear localization of the
telomeres (58, 119, 120), where it paradoxically prevents end joining of chromosomes
(121, 122). Since Ku70/80 binds DNA ends in a sequence independent manner, the
choice of joining or preventing joining of ends is dependent upon its interacting partners.
Studies in yeast and mammalian cells have shown that shelterine complex is crucial for
modulating Ku70/80 function at telomeres. Telomere dysregulation by knockouts of
shelterine proteins leads to chromosome-chromosome ligation, indicating that Ku70/80
lacks the ability to distinguish different types of DNA ends on its own (122, 123). The
exact regulatory mechanism of Ku70/80 function at telomeres remains an area of active
research (120, 121, 124, 125).
Ku70 and Ku80 share structural similarities in their core regions (Figure 7 and 8). Unlike
the Ku homodimer from prokaryotes, Ku70/80 in eukaryotes contains a von Willebrand
A (vWA) domain. The vWA domain serves as a regulator site and has been implicated in
interaction with auxiliary factors. Prokaryotic Ku is a homodimer and only contains the
core region, which resembles that of both Ku70 and Ku80 (126). Due to significant
sequence homology with the Gam protein of bacteriophage Mu, prokaryotic Ku is
proposed to have been acquired via lateral gene transfer. Similar to Ku from both
prokaryotes and eukaryotes, Gam binds DNA ends as a dimer and protects DNA ends
from nuclease digestion (127). Although both Ku70 and Ku80 possess additional
domains compared to more primitive organisms, Ku80 may be particularly evolved for
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function in NHEJ in eukaryotic organisms. This is likely as Ku80 is only found in
eukaryotes (128, 129). Furthermore, the mitochondrial Ku80 homolog harbours a Cterminal truncation that makes its size (68 kDa) similar to Ku70 (130). The C-terminal
region of Ku80 contains the DNA-PKcs interacting domain, suggesting the added
complexity of concerted DNA end-modification is an evolutionarily recent adaptation.
On the other hand, the C-terminus of Ku70 contains a SAP domain (a 35-residue motif,
named after the three proteins containing it: SAF-A/B, Acinus and PIAS) that has been
suggested to mediate at least some interaction with DNA. Indeed, similar SAP domains
from unrelated proteins have a conserved DNA binding activity (58). The SAP domain of
Ku70 is expected to play some role in modulating complex assembly on DNA ends
(131), but the actual function remains unclear.
Although Ku70 and Ku80 are structural homologs, they do not appear to carry out
redundant functions. Interestingly, investigation of the difference between Ku70/80
subunits suggests that at least one difference in function relates to DNA loading. Ku70/80
threads onto DNA ends with the Ku80 side first. Although the significance of this
preference is not understood, it has been suggested that heterodimeric Ku (as opposed to
homodimer Ku in prokaryotes) may provide a means for eukaryotic Ku70/80 to be
regulated for different roles in NHEJ, telomere maintenance and other activities (132).
The function of Ku70 and Ku80 has been explored through several mouse-model
knockout studies. Deletion of either Ku70 or Ku80 result in mice with SCID due to
defective ligation of V(D)J recombination (133, 134), γ-radiation hypersensitivity (133,
135), smaller size (136), and shortened life span due to early aging (137–139). Given this
shared phenotype and the intertwined nature of the Ku70/80 structure, the field has
traditionally understood that Ku70 and Ku80 are an obligate heterodimer. The first
evidence that this may not be the case came from knockout studies of individual Ku
subunits that demonstrated depletion of a single subunit does not diminish expression of
the other entirely, indicating that heterodimer formation is not obligatory for stabilizing
Ku70 or Ku80 (133, 136). Furthermore, with deficient levels of p53, Ku80 -/- mice
demonstrated increased incidence of cancer, with nearly 100% of mice dying from pro-Bcell lymphoma (135), while p53-/- Ku70-/- mice exhibited longer life span with less
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incidence of pro-B-cell lymphoma, with mortality largely due to medulloblastoma and Tcell lymphoma (140). A p53 knockout was important for separation of phenotypes
between Ku80-/- and Ku70-/-, as p53-mediated responses led to premature replicative
senescence and apoptosis, masking functional differences between Ku70 and Ku80
knockouts (135, 140, 141). This indicates that despite their well-known function as a
heterodimer, Ku70 and Ku80 likely possess individual functions independent of
heterodimer interactions.
Curiously, both Ku70 and Ku80 possess their own nuclear localization and are capable of
entering the nucleus independently, suggesting they may have functions independent of a
heterodimer complex (142–144). Moreover, Ku70 has been shown to interact directly
with Bax, suppressing its function in apoptosis. Importantly, when Ku70 interacts with
Bax it dissociates from Ku80, which suggests structural alterations depending on the
interaction state of Ku70 (145–148). Thus, despite early claims, a Ku70/80 heterodimer
may not be the exclusive means by which Ku70 and Ku80 function. Further structural
and functional studies will be required to understand independent roles of Ku70 and
Ku80.
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Figure 7. Domains of Ku70 and Ku80. Phosphorylation sites are denoted by their
residue numbers. vWA denotes the von Willebrand factor type A domains, NLS denotes
the nuclear localization signal sequences. Ku70 and Ku80 shows structurally conserved
vWA domains followed by Ku core domains. Their C-terminus differs as Ku70 possess a
SAP domain whereas Ku80 possesses a DNA-PKcs interacting region. Length of
functional domains is not to scale; linker regions <20 residues are omitted for clarity.
Figure 6 is adapted and summarized from (149).

23

Figure 8. Crystal structure of Ku70/80. (A) The red polypeptide chain represents Ku70
and the yellow polypeptide chain represents Ku80. (B) Ku70 domains are highlighted,
with the vWA domain in green, core domain in red, and SAP domain in cyan. The N- and
C-terminus of the protein is labelled, with missing density between the core and SAP
domain. Structure from PDB 1JEY is illustrated using PyMOL.
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1.3.5 PAXX
Paralog of XRCC4 and XLF (PAXX) is a recently discovered factor that appears to play
an auxiliary role in c-NHEJ (150–152). A partial structure of PAXX (residues 1-141)
revealed significant structural similarity with the N-terminal head domains of XRCC4
and XLF (151). Like XRCC4 and XLF, PAXX is predicted to be disordered in ~30% of
its C-terminal region and there is currently no structural information for the full-length
version of any of these related proteins.
Recent studies using gene knockouts have uncovered overlapping functions between
PAXX and XLF (151, 152). XLF but not PAXX knockout in mice shows dramatic
decrease in DSB repair functions (153). Although a single knockout of PAXX shows no
obvious defect in repair, a combined knockout of XLF and PAXX confers synthetic
lethality in mice (154). Similar to XLF, PAXX interacts with the Ku70/80 complex;
however, this interaction is mediated specifically through Ku70 and is dependent on
Ku70 interaction with DNA. The Ku70-PAXX interaction has been mapped to the Cterminal region of PAXX177-204 (151). On its own, PAXX does not appear to interact
stably with DNA; however, when Ku70 is pre-bound to DNA containing 10-15 extra
bases, PAXX binds with low micromolar affinity. The fact that Ku70 and extra DNA are
required for stable interaction suggests that PAXX makes direct contact with both Ku70
and DNA, but neither interaction is sufficient for stable binding on its own.
In addition to its interaction with Ku70, PAXX has been shown by immunoprecipitation
to interact with a number of other proteins. Surprisingly, these binding partners (PARP1
and DNA Ligase III) are involved in base excision repair and single strand break repair
pathways (74). This may indicate PAXX participates in more than one DNA repair
pathway, or perhaps is involved in recruitment of single-strand break repair factors for
sealing of the second strand at a DSB. Although PAXX appears to serve a backup
function for XLF during c-NHEJ, the mechanism of PAXX activity is only starting to be
examined and significant questions remain unanswered. Structural studies of the Ku70DNA-PAXX complex are required to provide the necessary information to begin
answering these questions.
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1.4 Thesis Objectives
The primary goal of work conducted in this thesis has been to gain structural knowledge
of NHEJ factors in higher-order assemblies to address the knowledge gap that exists for
understanding of their function in relation to structure and mechanism of action,
particularly when in complex and in interaction with DNA. One of the key limitations in
conducting such structural studies of NHEJ factors has been the inability to acquire high
concentrations of pure protein required for crystallization experiments. Thus, in the first
part of the thesis emphasis was placed on devising efficient methods for generating
sufficient amounts of several NHEJ proteins from a bacterial expression system.
Following biochemical characterization of purified proteins to ensure activity, structural
studies using X-ray crystallography were conducted for several different complexes
including: LX4, LX4-DNA, LX4-XLF-DNA, Ku70, Ku70-DNA, Ku70-DNA-PAXX.
Many crystallization parameters were investigated for each complex; however, as the
most promising crystals were obtained from screens of Ku70-DNA and Ku70-DNAPAXX, the focus of work was directed towards obtaining structural information for these
complexes.
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Chapter 2

2

Methods

This chapter outlines the specific procedures and materials utilized to carry out
experiments. The expression and purification procedures for all proteins underwent
numerous optimization variations in conditions for maximal yield and reproducibility.
Once sufficient protein was available, crystallization screening was performed using the
hanging drop vapour diffusion method. Following broad screening of various protein
complexes with DNA using commercial crystallization screen kits, promising leads were
reproduced with laboratory reagents to ensure the pre-made kit conditions were not
altered due to passage of time. Subsequently, crystallization conditions were varied to
determine optimal crystal formation. Typical parameters that were varied included: pH of
the buffer, protein concentration, precipitant concentration, temperature, and rate of
dehydration of the crystallization drops, and other individual components unique to a
given lead condition. Micro-crystals insufficient in size and/or quality for X-ray
diffraction data collection were optimized for growth and crystal quality with additive
screening, altered protein concentration and growth time. Once crystals of sufficient size
were obtained, X-ray screening was performed. Those crystals that yielded some amount
of diffraction were selected for further optimized using modified DNA substrates, altered
ratios of protein and DNA, and additional crystallization agent screening. High quality,
protein complex crystals were flash frozen in liquid nitrogen and data collected at the
Advanced Photon Source (APS) synchrotron in Chicago.

2.1 Plasmid Constructs
In order to improve levels of expression and prevent premature termination, recombinant
LX4 and Ku70/80 co-expression constructs were commercially synthesized following
codon optimization for bacteria (GenScript). The recombinant XLF construct was created
by Dr Sara Andres (68). Ku70 and PAXX constructs were generous gifts from Dr Mauro
Modesti (74). Details of each expression construct are described below.
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2.2 Protein Expression and Purification
2.2.1 DNA Ligase IV/XRCC4 (LX4)
In order to improve yield and purity of LX4 complex, full-length DNA Ligase IV was
cloned into the NdeI and XhoI sites of a pCOLADuet-1 co-expression vector with
addition of a N-terminal His9-tag followed by a TEV protease cleavage site. Full-length
XRCC4 was then cloned into the same vector using available NcoI and NotI sites. The
coding regions for Ligase IV and XRCC4 were codon optimized by GenScript. Rubidium
chloride (RbCl) competent BL21(DE3)-T1R cells were transformed with the expression
vector and grown on LB agar plates supplemented with kanamycin (50µg/mL). A single
transformant was selected and incubated in 10mL LB media supplemented with 50µg/mL
kanamycin at 37°C until OD600 reached 0.8, after which 1mL was subcultured into 1L
terrific broth (TB) supplemented with 50µg/mL kanamycin. Autoinduction was then
allowed to proceed at 20°C for ~60h.
Cells were harvested by centrifugation at 10,000g, washed with phosphate-buffered
saline (PBS) and re-suspended in lysis buffer (50mM Tris pH8.0, 2M NaCl, 10mM
imidazole, 0.4M ammonium acetate, 2mM β-mercaptoethanol, 5% v/v glycerol) prior to
storage at -80°C. Four protease inhibitors (1μM pepstatin A, 1mM
phenylmethylsulphonyl fluoride [PMSF], 1mM benzamidine, 10μM leupeptin) were
added before samples were lysed by four sequential passages through a French press.
Lysate was clarified by centrifugation at 50,000g, and applied to a 5ml Ni2+ charged
immobilized metal affinity column (Ni column; HisTrap HP, GE Healthcare). Bound
LX4 was washed with 10 column volumes (cv) of lysis buffer, then with 5-10 cv of lysis
buffer containing NaCl at a reduced concentration of 150mM. Further washes (10-20 cv)
were carried out with the same lysis buffer containing 75mM imidazole. Final elution
was performed by step-elution with lysis buffer supplemented with 500mM imidazole.
Eluted protein was exchanged into Q buffer (20mM Tris pH8.0, 150mM KCl, 1mM
EDTA, 10mM DTT, 10% v/v glycerol) and applied to a MonoQ 5/50 column (GE
Healthcare) equilibrated with Q buffer, and eluted with a linear gradient up to 300mM
KCl. Purified LX4 was buffer exchanged into storage buffer (20mM Tris pH8.0, 1mM
DTT, 100mM KCl, 20% v/v glycerol), concentrated to 10mg/mL using a 30kDa MWCO
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concentrator (Vivaspin 6, Sartorius stedim), flash frozen in liquid nitrogen, and then
stored at -80°C.

2.2.2 XLF
A pET-Duet1 plasmid (68) containing a full length XLF open reading frame with a Cterminal His6-tag was used to transform RbCl competent E. coli Rosetta™(DE3)pLysS
cells. Cell cultures were grown in LB supplemented with 100µg/mL ampicillin, and
expression induced with 1mM IPTG when OD600 reached 0.6. Incubation was continued
for 4h at 37°C prior to harvesting by centrifugation at 10,000g.
Cell pellet from 1L of cell culture growth was washed with PBS and re-suspended in
lysis buffer (20mM HEPES pH8, 2M NaCl, 10mM imidazole, 10mM βmercaptoethanol). Four protease inhibitors (1μM pepstatin A, 1mM PMSF, 1mM
benzamidine, 10μM leupeptin) were added before cells were lysed by four sequential
passages through a French press. Following clarification by centrifugation, soluble
protein was applied to a 5ml Ni column (HisTrap HP, GE Healthcare). After sequential
washes with lysis buffer containing 40mM and 90mM imidazole, XLF was step eluted
with buffer at 250mM imidazole. The eluent was exchanged into Hep buffer (20mM
HEPES pH8.0, 150mM NaCl, 1mM EDTA, 10mM β-mercaptoethanol) and applied to a
5mL Heparin column (HiTrap Heparin HP, GE Healthcare). XLF was eluted using a
linear gradient of Hep buffer from 0.15-1.0M NaCl at 1ml/min. Fractions containing pure
XLF were pooled, buffer exchanged into XLF storage buffer (20mM Tris pH8.0, 150mM
KCl, 1mM TCEP), concentrated to ~12mg/mL using 10kDa MWCO concentrator
(Vivaspin 6, Sartorius stedim), flash froze in liquid nitrogen, and stored at -80°C.

2.2.3 Ku70/80
A pCOLADuet-1-based co-expression system was constructed to express Ku70/80 within
a bacterial expression system. Ku805-545 with a N-terminus His9-tag was inserted into
available NcoI and NotI sites, while Ku7033-609 was cloned into NdeI and XhoI sites. The
construct domains were chosen based on the current crystal structure of Ku70/80 (PDB
1JEY) in order to specifically aid crystallography studies. E. coli BL21(DE3)-T1R cells
were transformed and colonies grown on LB agar plate supplemented with kanamycin
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(50µg/mL). A single transformant was incubated in LB supplemented with 50µg/mL
kanamycin until OD600~0.8. At this point, 10mL of culture was transferred to 1L of TB
media supplemented with 50µg/mL kanamycin and allowed to autoinduce at 20°C for
~60h.
Cell pellets were washed with PBS and re-suspended in lysis buffer (50mM Tris pH8.0,
1M NaCl, 10mM imidazole, 0.4M ammonium acetate, 2mM β-mercaptoethanol, 5% v/v
glycerol). Four protease inhibitors (1μM pepstatin A, 1mM PMSF, 1mM benzamidine,
10μM leupeptin) were added before cells were lysed by four sequential passage through a
French press. Lysate was clarified via centrifugation at 10,000g, and soluble protein
applied to a 5mL Ni column (HisTrap HP, GE Healthcare) equilibrated with lysis buffer.
Bound Ku70/80 was sequentially washed (10 cv) with lysis buffer, after which salt
concentration in the lysis buffer was reduced to a concentration of 50mM. A further wash
(10 cv) was performed with the same lysis buffer containing 45mM imidazole prior to
step-elution with 500mM imidazole. Eluted protein was directly applied to a Heparin
column (HiTrap Heparin HP, GE Healthcare), equilibrated with Hep buffer (50mM Tris,
pH8.0, 50mM NaCl, 0.5mM EDTA, 1mM DTT), and eluted using a linear gradient up to
1M NaCl. Purified Ku70/80 was buffer exchanged into storage buffer (50mM Tris pH8.0,
1mM EDTA, 1mM DTT, 100mM NaCl, 20% v/v glycerol), concentrated to ~11mg/mL
using 30kDa MWCO concentrator (Vivaspin 6, Sartorius stedim), flash frozen in liquid
nitrogen, and stored at -80°C.

2.2.4 Ku70
A pETDuet1 plasmid containing a full-length Ku70 open reading frame with a C-terminal
His6-tag was expressed in E. coli Rossetta™2 (DE3) cells. Cells were grown at 37°C in
LB media supplemented with ampicillin (100µg/mL) and expression induced with
0.5mM IPTG when cell density reached an OD600 of ~0.6. The cells were further grown
for 18h at 16°C prior to harvesting by centrifugation at 10,000g.
Cell pellets were washed with PBS and re-suspended in NiA buffer (50mM HEPES
pH7.5, 1M NaCl, 15mM imidazole, 0.4M ammonium acetate, 5% v/v glycerol, 2mM βmercaptoethanol). Four protease inhibitors (1μM pepstatin A, 1mM PMSF, 1mM
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benzamidine, 10μM leupeptin) were added before cells were lysed cells by four
sequential passages through a French press. Cell debris was removed by centrifugation
and the clarified lysate was applied to a 5mL Ni column (HisTrap HP, GE Healthcare)
equilibrated with Ni buffer. Protein which bound to the column was washed sequentially
(10 cv per wash) with NiA buffer, NiB buffer (50mM HEPES pH7.5, 100mM NaCl,
15mM imidazole, 5% v/v glycerol, 2mM βME), NiB buffer containing 50mM imidazole,
and step-eluted with NiB buffer containing 500mM imidazole. Eluted protein was
directly applied to a HiTrap Heparin HP column (GE Healthcare), equilibrated with Hep
buffer (50mM HEPES pH7.5, 5% v/v glycerol, 100mM NaCl, 0.5mM EDTA, 1mM
DTT). Bound protein was washed with 5 cv of Hep buffer containing 200mM NaCl, prior
to elution with a linear gradient from 200 to 400mM NaCl at 1 ml/min. Purified Ku70
was buffer exchanged into Ku storage buffer (20mM HEPES pH7.5, 100mM NaCl, 1mM
TCEP), concentrated to ~8mg/mL using 30kDa MWCO concentrator (Vivaspin 6,
Sartorius stedim), flash frozen in liquid nitrogen, and stored at -80°C.

2.2.5 PAXX
Full-length PAXX with a C-terminal His6-tag was inserted into the NdeI-BamHI sites of
a pHIS-parallel1 bacterial expression vector. E. coli Rossetta™ (DE3) pLysS cells were
transformed with the vector for expression. Cells were grown in LB media supplemented
with 100µg/mL ampicillin and 25µg/mL chloramphenicol until the density reached an
OD600 of ~0.6. The cell culture was chilled to 4°C by equilibrating the temperature slowly
in a cold room before being induced with 0.5mM IPTG for 16h at 15°C.
Cell pellets were washed with standard PBS buffer and re-suspended with lysis buffer
(20mM Tris pH8, 800mM NaCl, 10mM imidazole, 10% v/v glycerol, 2mM βmercaptoethanol). Four protease inhibitors (1μM pepstatin A, 1mM PMSF, 1mM
benzamidine, 10μM leupeptin) were added before cells were lysed cells by sonication
with three sequential 1min cycles. Cell debris was removed by centrifugation at 10,000g
and the clarified lysate was applied to a Ni column (HisTrap FF, GE Healthcare)
equilibrated with lysis buffer. Protein that bound to the column was washed sequentially
(10 cv) with lysis buffer containing 10mM and 30mM imidazole, and step-eluted with
buffer containing 300mM imidazole. Eluted protein was dialyzed into Q buffer (20mM
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HEPES pH8, 50mM NaCl, 1mM EDTA, 1mM DTT, 10% v/v glycerol), applied to a
HiTrap Q HP column (GE Healthcare) equilibrated with Q buffer, and eluted with a
linear gradient from 50 to 400mM KCl. Purified PAXX was dialyzed into storage buffer
(20mM HEPES pH8, 150mM NaCl, 1mM TCEP, 10% v/v glycerol), concentrated to
~4.9mg/mL using 10kDa MWCO concentrator (Vivaspin 6, Sartorius stedim), flash
frozen in liquid nitrogen, and stored at -80°C.

2.3 Protein Quantification
Bradford assays were performed for determination of protein concentration using
Pierce™ Coomassie Plus (Bradford) Assay Kit (Thermo Fisher) according to the
manufacturer’s user instructions.

2.4 SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was
performed by applying samples to a 9-15% w/v acrylamide gel supplemented with 0.1%
v/v 2,2,2-Trichloroethanol. Electrophoresis was performed at 150V for ~60min using a
Mini-PROTEAN® Tetra Vertical Electrophoresis Cell (Bio-Rad). Gels were directly
visualized with UV photo-activation or conventional Coomassie Blue staining followed
by imaging using a Gel Doc™ EZ Gel Documentation System (Bio-Rad).

2.5 Western Blot
Following separation by SDS-PAGE, the gel was stacked with a polyvinylidene
difluoride membrane pre-wet with 100% methanol. The transfer was carried out in
transfer buffer (50mM Tris pH8.0, 40mM glycine, 20% v/v methanol) using the Bio-Rad
Trans-Blot Turbo transfer system (Bio-Rad), at 75 amperes for 115min. The membrane
was then blocked in generic 5% w/v fat-free powdered milk dissolved in Tris buffered
saline (TBS; 50mM Tris pH8, 150mM NaCl) supplemented with 0.05% v/v Tween-20
(TBS-T) for 1h at room temperature. After blocking, the membrane was incubated with
Ku70 (N3H10) antibody (Santa Cruz) diluted in 3% w/v fat-free powdered milk in TBST at 4°C for 18h with slow shaking. Ku70 antibody was a generous gift from Dr Caroline
Schild-Poulter. The blot was rinsed three times using TBS with 3% w/v milk before
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being incubated with mouse-specific alkaline phosphatase-conjugated secondary
antibody. The membrane was then washed (TBS-T with 3% w/v milk) three times for
20min, once with TBS, and finally developed using AP Conjugate Substrate Kit (BioRad), incubated for 10min before the membrane was rinsed with water. Images of
western blots were collected using a generic camera.

2.6 SEC-MALS Analysis
Size exclusion chromatography coupled with multi-angle light scattering (SEC-MALS)
experiments were performed at 4°C, with an in-line Superdex 200 GL size-exclusion
column (GE Healthcare) at a flow rate of 0.5mL/min. Light-scattering experiments
utilized 18 angles to determine the mass of protein in a given peak eluted during SEC.
Prior to performing SEC-MALS, purified proteins were diluted to 2mg/mL using storage
buffer (50mM HEPES pH7.5, 100mM NaCl, 1mM TCEP). Samples were centrifuged at
20,000g for 60sec to remove any large particulate, and injected onto a Superdex 200
10/300 GL size-exclusion column (GE Healthcare) equilibrated with the same storage
buffer. Eluted sample was detected by a DAWN HELEOS light scattering detector at a
wavelength of 662nm, connected in tandem to an Optilab refractive index concentration
detector using a wavelength of 658nm (Wyatt Technology). A refractive index increment
of 0.185 was used. The light scattering data was collected and displayed by ASTRA
(version 6.1.5.22, Wyatt Technology).

2.7 DNA Ligation Assay
In order to ensure that recombinant LX4 sample was fully active, ligation capacity of
purified LX4 was tested. A linear DNA substrate of ~2686bp with compatible ends (4
base 5’ overhang) was generated by restriction digest of pUC19 using HindIII (NEB) by
incubating at 37°C for 1h in Buffer R as per manufacturer’s recommendation.
Subsequently, 100pmol of LX4 was incubated with 200ng of linearized pUC19 in T4
ligation buffer (NEB) in a final reaction volume of 20μL at 21°C for 1h. Subsequently,
1μL of Proteinase K (Thermo Fisher) was added and incubated at 50°C for 30min to
terminate the reaction and remove all protein bound to DNA. Ligation reactions were
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resolved on a 0.8% w/v 0.5x TBE agarose gel run in 0.5x TBE buffer at 50V for 145min
and visualized by immersing the gel in sufficient volume of 0.5µg/mL ethidium bromide
for 15min with agitation, followed by incubating in water for 15min with agitation. Gel
imaging used a Gel Doc™ EZ Gel Documentation System (Bio-Rad) for qualitative
analysis.

2.8 DNA Substrates for Crystallography
A critical feature of successful crystallization is ensuring a homogeneous, mono-disperse
sample prior to crystallization. In this regard, selecting the correct type of DNA is
essential. To stabilize a LX4 complex for optimal crystallization, two different types of
DNA substrates were chosen for their ability to achieve interruption of the ligation
reaction, effectively trapping the enzyme at discrete steps before ligation is complete. For
ligation reaction to occur, first the active site lysine in DNA Ligase IV is loaded with an
adenylyl group, which subsequently undergoes a SN2 reaction by the free electron pair on
the 5’ phosphate of the broken DNA end base (155). This AMPylation of the 5’
phosphate allows it to become a better leaving group for a second S N2 reaction using
attack by an activated 3’ hydroxy group of the upstream strand, completing the ligation
reaction. Hence there are two steps in this mechanism that can stall the ligation reaction.
First, if the downstream strand does not contain a 5’ phosphate group, there can be no
AMPylation for a second SN2 reaction, blocking ligation. Alternatively, a
dideoxyribonucleic acid on the 3’ end of the upstream strand will also disable the reaction
due to the lack of a 3’ hydroxyl group. Utilizing these two strategies, we formulated
different DNA substrate designs to screen for LX4-DNA crystal formation (Appendix 1
and 2). Various duplex and multiplex substrates were made with synthesized DNA
oligonucleotides for the crystallization trials (Appendix 1). DNA oligonucleotides are
synthesized by Bio Basic. Annealing of different DNA substrates was performed by
mixing equimolar amounts of oligonucleotide to a final concentration of 100μM and
heating to 95°C prior to slow cooling (1°C per minute) using a thermocycler (Thermo
Fisher). Specific DNA substrates named and used for crystal screening are listed in
Appendix 2.
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2.9 Electrophoretic Mobility Shift Assay
In order to determine the ability and extent of protein-DNA interaction, electrophoretic
mobility shift analysis (EMSA) was performed using recombinant proteins. In these
studies, purified protein and DNA substrate were mixed in EMSA buffer (75mM KCl,
10mM Tris pH7.5, 0.5mM EDTA, 0.5mM DTT, 5% v/v glycerol) in a final volume of
10μL and allowed to incubate at room temperature for 30min. The amount of DNA added
varied as indicated. Purified protein was diluted to varying concentrations prior to adding
to EMSA reactions. DNA loading dye (30% v/v glycerol, 0.25% w/v bromophenol blue,
0.25% w/v xylene cyanol FF) was added to each reaction sample, and DNA components
(bound vs free) fractionated by 6% w/v polyacrylamide gel electrophoresis in 0.5x
standard TBE buffer at 80V for 45min. The gel was stained with 0.2μg/ml ethidium
bromide (EtBr) for 20min and de-stained in water for 15min before being visualized
using a ChemDoc system set at a wavelength of 356nm (Bio-Rad).

2.10 Crystallography
All crystallization was performed using the hanging drop vapour diffusion method. Initial
screening for suitable crystallization conditions to generate protein crystals was
performed by mixing 1μL volumes of protein (at varying concentrations) with
crystallization conditions obtained from commercial vendors including the MCSG Suites
(Anatrace/Microlytic), Wizard series (Rigaku), PACT premier™ (Molecular
Dimensions), NeXtal Classic Suite (QIAGEN). Four 96-condition kits were selected for
investigating the suitable concentration of protein to yield informative screening results.
Once a suitable concentration for screening was determined, additional sparse matrix
screening was performed with additional 96-condition kits to obtain a broad range of
variation of crystallization components for maximal screening success. Similar
procedures were employed to generate protein-DNA crystals. The protein-DNA complex
was first formed by mixing protein and DNA at an appropriate molar ratio (typically
close to 1:1). Depending on the type of complex and desired buffer components and final
concentration of complex, the sample was either concentrated through a Nanosep ®
Centrifugal Device (PALL) or dialyzed into desired buffer. Crystallization trials were
performed by mixing 1μL volumes of protein-DNA complex and crystallization
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conditions listed above. All crystallization mixtures are equilibrated over 1mL of 1.5M
(NH4)2SO4 as reservoir solution, which functioned to slowly dehydrate crystallization
sample. Depending on the general trend of solubility, reservoir solution was replaced
with higher or lower concentration of (NH4)2SO4 for manipulating a desirable level of
sample precipitation. Crystallization was performed at 20 and 4°C.
The progress of protein crystallizations was assessed and imaged using a Nikon
SMZ1500 zoom stereomicroscope mounted with a Nikon Coolpix 4500 digital camera.

2.10.1 Crystallization of LX4, LX4-DNA, LX4-XLF-DNA
Purified LX4, LX4-DNA, and LX4-DNA-XLF underwent crystallization screens using
sparse matrix screening kit conditions MCSG I and II (Anatrace) and Wizard I and II
(Rigaku). In all cases, the starting protein concentration was ~10mg/mL and the same
500 conditions were used sparse matrix screening. LX4 and the DNA substrate were
mixed to a molar ratio of 1:1. Unless otherwise specified, crystallization trials were
screened at 4°C. For the protein mixture to reach metastable phase, crystallization
mixtures were equilibrated against 800μL of 2M (NH4)2SO4 for dehydration.

2.10.2 Crystallization of Ku70, Ku70-DNA, Ku70-DNA-PAXX
Initial crystallization screens of Ku70, Ku70-DNA, and Ku70-DNA-PAXX employed
condition kits MCSG I - IV (Anatrace), Wizard I and II (Rigaku), and NeXtal Classic
Suite (QIAGEN). For Ku70-DNA complex, Ku70 and the DNA substrate were initially
mixed to a molar ratio of 1:1.2, which later increased to 1:1.5 after optimization. For
Ku70-DNA-PAXX complex, Ku70 and the DNA substrate were first mixed to a molar
ratio of 1:1.5, after which PAXX was added in equimolar ratio to Ku70. Unless otherwise
specified, crystallization trials were performed at 20°C.
Initial microcrystals of Ku70-DNA complex were obtained in two crystallization
conditions: MCSG I #95 (0.2M NaCl, 0.1M HEPES pH7.5, 25% w/v PEG3350;
Anatrace) and MCSG II #80 (0.1M Tris pH7, 20% w/v PEG1000; Anatrace). These
conditions were reproduced using lab reagent NaCl (BioShop), HEPES (Bio Basic),
PEG3350 (Bio Basic), Tris (BioShop), and PEG1000 (Bio Basic). Crystal morphology
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was improved through successive variation of parameters including: pH, salt identity and
concentration, PEG molecular weight and concentration, additive screens (Silver Bullets,
Additive Screen; Hampton), as well as drop volume and ratio of protein mixed with
crystallization condition. Chapter 3.5 details the sequential improvement of crystal
morphology, which correlated with enhanced diffraction data resolution, and the principle
factors influencing the crystallization process.

2.10.3 Optimization of Ku70-DNA and Ku70-DNA-PAXX Crystals
DNA substrates were designed in three structural groups to help improve crystallization
success by increasing potential crystal contacts. While a duplex region is required for
Ku70 binding, one end of the DNA was modified with a stem-loop structure, Y-shaped
fork, or polythymine tail to obstruct potential movements once Ku70 dimer was bound.
Duplex length was varied to optimize the stability of protein-DNA interaction (Appendix
2). For initial screening of crystallization conditions, Ku70 dimer was mixed with loop14,
the DNA substrate, at a 1:1.2 molar ratio with DNA in excess. The final concentration of
Ku70 was maintained at 4mg/mL. Later on, other variables were explored including:
DNA length/structure, DNA concentration, incubation temperature, small molecule
additives, drop ratio, concentration of dehydration solution in reservoir, and individual
components of the crystallization conditions that yielded initial hits.
The diffraction data quality of crystals containing Ku70 complexed with DNA were
enhanced by varying the structure of DNA substrates. Crystallization trials were
performed with conditions from the following screens: MCSG I - IV (Anatrace), Wizard I
and II (Rigaku), NeXtal Classic Suite (QIAGEN), The PEGs Suite (QIAGEN), PEGRx
(Hampton), PEG smear conditions (made with lab reagents, composition adpted from
Chaikuad et al.). Later optimization screens employed included the Silver Bullets
(Hampton) screen and Additive Screen (Hampton).

2.11 X-ray Diffraction Data Collection
Initial screening of crystals was performed using a MicroMax-007 HF X-ray generator
mounted with VariMax optics and Raxis 4++ detector (Rigaku). Crystals were directly
mounted on pins and flash frozen in the cryo-jet stream held at 100 Kelvin.
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High resolution diffraction data were collected at the APS, a USA national synchrotronradiation light source research facility (Argonne, IL, USA).

2.12 Structural Determination and Refinement
Diffraction data were indexed, integrated, and scaled with iMOSFLM of the CCP4 suite
(157). The structure of PAXX was solved using PDB 3WTF as a search model for
molecular replacement performed using Phenix (158). The initial model was refined
using iterative cycles of phenix.refine (159) and manual model adjustment using coot
(160) until R values converged.
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Chapter 3

3

Results

In this chapter, advances made towards structural determination of NHEJ factors in
higher order assemblies are described. These include: modification of expression and
purification methods to substantially increase NHEJ protein availability, development of
novel LX4 and Ku70/80 bacterial co-expression constructs, expression and
characterization of a novel Ku70 homodimer from bacteria, and crystallization of Ku70DNA and PAXX.

3.1 Improvements in Production of NHEJ Factors
The first step toward enabling crystallographic studies of NHEJ assemblies is achieving
methods for easy acquisition of milligram amounts of soluble and purified protein. To
this end, the general strategy taken (for LX4, Ku70/80 and Ku70) involved developing
novel expression methods (optimizing domain boundaries, codon usage, construction of
co-expression vectors, choice of bacterial strain for expression, etc.). Previous systems
for expression of XLF (161) and PAXX (74) were also adapted from the literature and
modified to maximize yield and reproducibility. Collectively, this work resulted in
desired improvements for expression and purification with the highest reported yields to
date for LX4, XLF, Ku70/80, Ku70 and PAXX (Table 2).

3.1.1 Purification of LX4, XLF and Ku70/80
Using existing methods for production of LX4 were prohibitive for structural studies due
to low yield and purity. Consequently, a new LX4 construct was engineered to explore
improvements in expression and purification quality. Since XRCC4 is typically expressed
at higher levels than Ligase IV, and Ligase IV is unstable when unbound to XRCC4, a
His9-tag was added to Ligase IV instead of XRCC4 so that LX4 will co-elute as a
complex during purification. Additionally, both human open reading frames were codon
optimized for bacterial expression. This co-expression vector led to more than 10-fold
increase in production efficiency compared to previous vectors (161) (Table 2). The
purification procedure was also able to be simplified by reducing the number of columns
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from three (IMAC followed by two types of ion exchange) to two (IMAC and ion
exchange) (Figure 9). A significant amount of LX4 complex was required for
crystallization screening due to the relatively high degree of LX4 solubility, which
warranted screening at higher than usual protein concentrations. Using the method for
LX4 expression and purification developed here, LX4 could be maintained in a soluble,
stable state at >15mg/mL making further structural studies feasible.
Two different XLF expression and purification protocols were previously established
(162, 163), with the main differences being choice of bacterial strain, purification buffer
components and chromatography column choices. After comparing purification
efficiency and replicability between these two methods, one was chosen for further
optimization (Figure 10). Use of E. coli Rosetta™(DE3)pLysS cells for expression led to
a reduction in XLF degradation, among other contaminants (Appendix 3), presumably
due to an enhanced ability of these cells to express eukaryotic proteins that contain
codons rarely used in E. coli. Although XLF is not highly toxic to bacteria, use of
Rosetta™(DE3)pLysS cells permitted better control over leaky expression that may also
have helped to improve protein yield and quality. Another important alteration to XLF
production came from changing the type of ion exchange column from a MonoQ to
Heparin, which resulted in better resolution of protein elution. Heparin not only acts as a
general ion exchange resin, but also mimics some aspects of DNA and is therefore often
more suitable for purification of DNA binding proteins (164). Further details of the final
protocol developed for XLF expression and purification are presented in Chapter 2.2.2.
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Figure 9. Representative purification of LX4 complex. Lane 1 shows the soluble
fraction of proteins applied to Ni column; lane 2 shows protein extracted from insoluble
sample of cell lysate; lane 3 shows unbound protein; lane 4 shows protein eluted by
buffer solution with elevated imidazole concentration; lane 5 shows sample eluted from
Ni column; lane 6 shows the purified LX4 eluted from MonoQ column.
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Previous methods for generating Ku70/80 required expression in insect cells, which is
both time consuming and expensive. A new Ku70/80 bacterial co-expression construct
was designed based on domain boundaries from the current crystal structure. Following
codon optimization, this co-expression vector showed Ku70/80 expression using either
IPTG induction in E. coli Rosetta™ 2(DE3), or auto-induction in BL21(DE3)-T1 R.
Because of increased levels of expression, auto-induction was chosen for large scale
production of Ku70/80. Unfortunately, both Ku70 and Ku80 migrated at the same
position when resolved by SDS-PAGE. Since Ku80 was tagged with a His 9-fusion for
purification by IMAC, a Ku70-specific antibody was used to confirm its presence in the
co-migrating bands (Figure 11). A previous purification protocol for Ku70/80 expressed
from bacterial cells (165) was used as a starting point for further modification based on
empirical evidence of protein yield and purity. The final optimized protocol for bacterial
co-expression of Ku70/80 produced ~1.2mg of pure protein from 1L of cell culture
growth and therefore provides a significant improvement to the ease and cost in
preparation of Ku70/80 for future structural studies involving complexes formed by
Ku70/80 (Figure 12).
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Figure 10. Purification of XLF. A representative purification profile of XLF is shown,
where the arrow indicates the expected size of XLF. Lane 1 shows the soluble fraction of
proteins applied to Ni column; lane 2 shows unbound protein; lane 3 and 4 shows protein
eluted with elevated imidazole concentration; lane 5 shows the eluted protein from Ni
column; lane 6 shows unbound protein from the Heparin column; lane 7 shows the final
purified XLF eluted from Heparin column. The lanes are rearranged from the original gel
for better comparison.
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Figure 11. Ku70/80 Autoinduction profile. Lane 1, cell growth after 3h mirrors
uninduced state of typical LB+IPTG induction system. lane 2, after 60h of cell growth,
the level of Ku70 induction is similar to that of IPTG induced cells. lane 3, western
blotting was performed with Ku70-specific antibodies showing no induction. lane 4,
purified Ku70/80 sample (from Lane 8, Figure 12) allows much clearer identification of
Ku70 induction.
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Figure 12. Purification of Ku70/80. Lane 1 shows the soluble fraction of proteins
applied to Ni column; lane 2 shows unbound protein; lane 3 shows protein eluted with
buffer of decreased ionic strength; lane 4, 5 and 6 shows contaminants from elevated
imidazole washes; lane 7 shows the eluted protein from Ni column; lane 8 shows the final
purified Ku70/80 eluted from a Heparin column.
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3.1.2 Purification of Ku70 and PAXX
Recent reports in the literature suggest that Ku70 and Ku80 may not function entirely as a
heterodimer. This and the fact that Ku70 interacts specifically with other factors such as
PAXX, suggested that structural studies of Ku70 alone would be of interest. Contrary to
what the field would expect, expression and purification of Ku70 was readily achieved in
the absence of Ku80 from bacterial cells. Purification of full-length Ku70 utilized a
nickel affinity chromatography step in which elution from the IMAC column was
performed in tandem with an inline Heparin column to minimize time and sample loss.
This method resulted in high yield and very desirable purity for Ku70 (Figure 13). While
the protein remained in solution during concentration up to ~8mg/mL with no significant
precipitation, Ku70 appeared to be more stable in the presence of DNA. Qualitative
assessment showed that a sample of Ku70 became cloudy after prolonged storage at 4°C,
but regained transparency once DNA was added.
High level expression and methods for efficient purification have been reported for
PAXX, and therefore no significant modifications were required for PAXX production
used in structural studies with Ku70-DNA (162; Figure 14). In order to minimize
component variability when producing Ku70-PAXX-DNA complex for crystallization,
the final PAXX storage buffer was modified to resemble that of Ku70 storage buffer.
A comparison of protein production efficiency for all NHEJ factors used for screening of
crystallization conditions is presented in Table 2. In all cases, the amount of pure protein
produced from a single litre of bacterial cell growth exceeded 1mg making these proteins
amenable to further structural studies using X-ray crystallography.
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Figure 13. Purification of Ku70. Lane 1 shows the soluble fraction of proteins applied
to Ni column; lane 2 shows unbound protein; lane 3 shows protein eluted with buffer of
decreased ionic strength; lane 4 and 5 shows contaminants from elevated imidazole
washes; eluted protein was directly applied to a Heparin column, with lane 6 showing the
final eluted Ku70 sample. Gel lanes are contracted for clarity.
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Figure 14. Purification of PAXX. Lane 1 shows the total protein from induced cells;
lane 2 shows the soluble fraction of proteins applied to Ni column; lane 3 shows unbound
protein; lane 4 and 5 shows contaminants from elevated imidazole washes; lane 6 shows
the eluted protein from Ni column; lane 7 shows the final eluted PAXX sample. The
lanes are rearranged for clarity.
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Table 2. Summary of purification yield of NHEJ factors. Extraction ratio is in relation
to the total E. coli protein from clarified lysate of 1L of cell growth.
LX4
Soluble lysate
Ni elution
MonoQ elution

Total protein (mg)
205.2
14.3
10.9

Extract ratio (%)
100.0%
7.0%
5.3%

XLF
Soluble lysate
Ni elution
Heparin elution

Total protein (mg)
156.5
18.6
12.8

Extract ratio (%)
100.0%
11.9%
8.2%

Ku70/80
Soluble lysate
Ni elution
Heparin elution

Total protein (mg)
318.1
3.5
1.2

Extract ratio (%)
100.0%
1.1%
0.4%

Ku70
Soluble lysate
Ni elute
Heparin elution

Total protein (mg)
209.1
8.0
3.7

Extract ratio (%)
100.0%
3.8%
1.8%

PAXX
Soluble lysate
Ni elution
MonoQ elution

Total protein (mg)
92.7
29.8
15.8

Extract ratio (%)
100.0%
32.1%
17.0%
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3.2 Purified LX4 Retains Ligation Activity
The functional fidelity of LX4 generated from bacterial co-expression was assessed using
a standard DNA ligation assay. Purified LX4 sample exhibited robust ligation activity
with a HindIII linearized pUC19 DNA substrate containing compatible ends (Figure 15).
Typical of LX4 from insect and mammalian cell expression, bacterial LX4 protein
produced intermolecular ligation products corresponding to two, three, and four pUC19
linear plasmids ligated together.
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Figure 15. DNA ligation assay showing LX4 activity. Lane 1 shows a 1kb DNA Ladder
(Geneaid); lane 2 shows supercoiled pUC19 plasmid; lane 3 shows pUC19 linearized
with HindIII; lane 4 shows DNA ligation products generated by purified LX4 complex
after 1h incubation at 21°C using identical amount of DNA as lane 3.

51

3.3 Ku70 Forms a Stable Dimer in Solution
Although Ku70 and Ku80 may function independent of heterodimer formation in cells,
whether this involves self-oligomerization is not known. Using SEC-MALS, the
molecular mass of species in a solution can be accurately determined. Purified Ku70 was
applied to a size-exclusion column, where a single species of protein complex eluted. By
placing the MALS detector in tandem with the size exclusion column, a light scattering
profile of the eluted protein was found to be ~140kDa, indicating that Ku70 forms a
homodimer in solution (Figure 16). Complex formation with DNA did not alter this
oligomeric state (Appendix 4). Importantly, results from this analysis indicate that Ku70
exists in a defined (monodisperse) state in solution, suggesting that it is well suited for Xray crystallographic studies. As well, the fact that Ku70 forms a homodimer in solution
further suggests that this quaternary structure may represent the Ku70 structure
responsible for Ku80-independent functions (167, 168). To examine and compare the
Ku70 homodimer with that of Ku70/80, structural studies of Ku70 were performed for
the DNA-bound and unbound states (see section 3.6).
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Figure 16. SEC-MALS data showing stable dimer of Ku70 in solution. The left y-axis
indicates the estimated molecular mass of the sample, corresponding to the dotted line;
right y-axis indicates the UV absorbance scale of the eluted protein, corresponding to the
solid line; x-axis indicates the elution time of sample from the size exclusion column
(flow rate ~0.5mL/min).
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3.4 Ku70 Homodimer Exhibits DNA Binding Activity
Although Ku70 was shown to exist as a stable homodimer in solution, it remained
possible that some misfolding had occurred. In order to verify the functional integrity of
Ku70, its DNA binding capacity was determined using EMSA analysis. As shown in
Figure 17, Ku70 homodimer readily shifted 16bp DNA with an apparent affinity in the
low micromolar range. Thus, Ku70 DNA binding capacity was found to be similar to that
previously reported for Ku70/80 produced in insect cells. Taken together, results from the
characterization of bacterial expressed Ku70 suggest that Ku70 is well suited for
structural studies in complex with DNA or other binding partners such as PAXX.

54

Figure 17. Analysis of Ku70 DNA binding activity with loop16 DNA substrate. The
arrows indicate the species of Ku70-bound DNA. Samples were separated on an 8% w/v
polyacrylamide gel, and DNA visualized by staining with ethidium bromide.
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3.5 Crystallization Screening of LX4, LX4-DNA and LX4XLF-DNA
Building on success in obtaining large amount of soluble, functional NHEJ factors, sparse
matrix screening trials were performed to determine crystallization conditions to enable
structure determination of several LX4-based complexes including: LX4, LX4 with
DNA, LX4 with XLF and DNA. Due to the dynamic nature of filament formation that is
proposed to coordinate the ligation complex, crystallization strategies needed to consider
DNA substrates that were designed to simulate ligation, but at the same time selectively
limit the flexibility of the filamentous interactions of the complex. Here we produced
three types of rationally designed substrates that focused on facilitating complex
assembly without ability to complete ligation, effectively “stalling” the complex and
capturing a monodisperse sample on DNA ends (Appendix 2). The first substrate used
(18stall) contained a dideoxyribonucleotide at the 3’end of the nicked strand nicked,
disabling its ability to attack the AMPylated 5’ phosphate on the opposite strand,
effectively stalling the reaction before the final ligation could be carried out. The second
substrate (stack9) contained a 5’-OH at the nick site and therefore prevented initial
AMPylation. This substrate contained cohesive ends that allowed elongated DNA
structures to assemble in tandem. This design was chosen with the hope that such a
substrate might assist in formation of an orderly lattice. Similar DNA substrates have
been used successfully for crystallization of XRCC4/XLF complexes (Chris Brown,
unpublished data). Since prior crystallization trials (161) were attempted without success
at 20°C, and a lower temperature often increases protein stability, crystal screening for
LX4 was initially conducted at 4°C.
LX4 was found to be highly soluble. Even when a starting concentration of 10mg/mL
was used for sparse matrix crystal screening, most of the drops remained clear. This
suggests a higher protein concentration may be optimal for screening. Nevertheless,
under these conditions, two different crystal morphologies were identified (Figure 18). Xray diffraction was carried out on both crystals; however, neither crystal showed any
diffraction. Thus, significant additional optimization of these crystallization conditions
would be required to yield diffraction quality crystals.
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Overall, LX4 complex remained soluble in ~65% of sparse matrix conditions tested and
precipitated in the remaining 35% of conditions. As an ideal ratio of conditions resulting
in soluble or precipitated protein is about 1:3 so that the protein complex would reach
supersaturated state in most conditions, subsequent screening of LX4-DNA complex was
performed with the final LX4 complex concentration increased to 11mg/mL. Despite the
higher concentration of protein complex used, the screens still gave results with about
50% soluble protein. This finding suggests that, despite a higher concentration of the
final complex, the addition of DNA led to less precipitation of the protein complex
compared to LX4 crystallization performed in the absence of DNA. Although such an
effect is often associated with increased stabilization that can lead to greater success in
crystallization, few crystallization hits were obtained under these conditions. Further
screening could therefore be performed using higher concentrations of LX4-DNA
complex. With this in mind, screening for crystallization conditions of LX4-XLF-DNA
was carried out at concentrations of 50μM LX4, 100μM XLF and 50μM DNA, reflecting
a 1:2:1 molar ratio as predicted by structural modelling (163). This resulted in better
outcomes with only ~25% of conditions showing a lack of precipitation. After two
months of vapour equilibration, no crystals were observed and therefore the temperature
was adjusted from 4°C to 20°C for further evaluation.
Since the results of initial crystal screening for LX4 complexes was less promising than
those of Ku70 and PAXX (see section 3.6), and a decision was made to pursue an M.Sc.
instead of a Ph.D., subsequent structural pursuits were focused towards Ku70, Ku70DNA and Ku70-DNA-PAXX complexes.
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Figure 18. Unoptimized LX4 crystals. Crystals appeared after 3–4 weeks with
11mg/mL LX4 complex in 0.2M ammonium acetate, 0.1M Tris8.5, 25% (w/v) PEG3350.
The drop was set at 1:1 protein to condition volume ratio, and incubated at 4°C. Two
distinct crystal morphologies formed (polygonal with radiating needles, and hexagonal)
with the most dominant form being hexagonal.
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3.6 Crystallization of Ku70 and Ku70-DNA
Several concentrations of Ku70 were initially tested for overall suitability for broad
sparse matrix crystal screening. A concentration of 4mg/mL was determined to yield the
most informative results from crystallization trials using commercially available kits. At
this concentration, approximately 75% of the screened conditions resulted in drops with
significant protein precipitation. Despite extensive screening using sparse matrix
sampling, no promising leads were found. Several conditions generated microcrystals that
did not diffract. Further optimization through additive screen, volume ratio and
dehydration variance did not improve their crystal growth nor X-ray diffraction quality
(Figure 19, Appendix 5). Ku70 alone may have too much structural flexibility in the
absence of DNA to readily accommodate ordered crystal lattice interactions.
In contrast to Ku70 alone, promising leads were obtained upon screening of Ku70-DNA
complex at similar concentrations (Figure 20, Appendix 6). Microcrystals resulting from
Ku70-loop14 complex screening were tested by X-diffraction. Diffraction at low
resolution was observed for microcrystals from several crystallization conditions,
suggesting that crystals were formed from protein and not salt. This interpretation was
further supported by lack of crystal formation in negative controls that contained all
crystallization components except Ku70 and/or loop14 DNA. The fact that crystals with
similar morphology were grown in several different crystallization conditions suggested
that the crystal would likely be amenable to optimization of improved growth and
diffraction quality. Because crystal quality of protein-DNA complexes is notoriously
dependent on DNA length and end structure, subsequent screening efforts were focused
on exploring the effect of different DNA substrates. DNA substrate that was 14bp in
length with an additional single base overhang on each strand showed propensity to
crystallize on its own, reflected in their small unit cell sizes of 26.48, 26.48, 64.71 and
27.01, 27.01, 58.92, respectively (Figure 21). This likely occurred since the substrate
corresponded to ~1.5 helical turns of DNA, allowing easier packing into the structured
lattices of a crystal. The results from the overall screening of Ku70 with various types of
DNA substrate are summarized in Appendix 6. Out of 40 crystals identified from sparse
matrix screens, 24 were composed of salt; 2 were DNA alone; 11 were non-diffracting
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due to small size or poor crystal packing and could not be improved by further
optimizations; and 3 represented promising leads. Promising initial crystallization
conditions were obtained from the following kits: Wizard I #10, MCSG II #80, and
MCSG I #95 (Figure 22, Table 3).
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Figure 19. Typical Ku70 non-diffracting microcrystals. The red circle highlights one
of the rectangular shaped microcrystals among precipitation. The crystal shown was
formed in 0.2M calcium acetate, 0.1M imidazole pH8, 20% w/v PEG1000. The drop was
set with 1:1 protein to condition volume ratio, and incubated at 20°C.

Figure 20. Initial hits of Ku70-DNA crystals. These crystals were detected in mixtures
with Ku70-loop16, under (A) 0.2M sodium chloride, 0.1M HEPES pH7.5, 25% w/v
PEG3350 and (B) 0.1M Tris pH7, 20% w/v PEG1000. The drops were set with 1:1
protein to condition volume ratio, and incubated at 20°C.
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Figure 21. DNA crystals obtained from Ku70-DNA complex crystallization. In a
different DNA substrate, the 14bp duplex DNA with thymine overhangs crystallized on
its own. (A) shows crystals of 14b3T and (B) that of 14b1T.

Figure 22. Diffraction patterns of the initial hits of Ku70-DNA. The diffraction
pattern shows low resolution diffraction spots close to the direct X-ray beam. The red
ring represents the resolution range for ~8Å diffraction. Both crystals exhibited low
resolution diffraction ~15Å. (A) Ku70-DNA was crystallized in 0.2M sodium chloride,
0.1M HEPES pH7.5, 25% w/v PEG3350, and (B) 0.1M Tris pH7, 20% w/v PEG1000.
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Table 3. Components of promising Ku70-DNA crystallization conditions.
Name

Salt

Buffer

Precipitant

MCSG I #95

0.2M sodium chloride

0.1M HEPES pH7.5

25% w/v PEG3350

MCSG II #80

0.1M Tris pH7

20% w/v PEG1000

Wizard I #10

0.1M Tris pH7

20% w/v PEG2000
MME
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3.7 Optimization of Ku70-DNA Crystals Improved
Diffraction Data Quality
After identifying several promising lead crystallization conditions for Ku70-DNA
complex, further optimization was performed using additive screening and volume ratio
variation. From this analysis, MCSG II #80 and MCSG I #95 were shown to be the most
promising conditions and both conditions were optimized further in parallel.
Preliminary optimization yielded inconsistent nucleation events and the crystal
morphology remained poorly defined. By varying the structures and lengths of the DNA
duplex employed in crystallization trials, we found that DNA containing a defined stemloop structure and varying duplex length resulted in improved crystal growth
reproducibility. In particular, loop16 DNA with its increased length of duplex, compared
to loop14, resulted in better crystal morphology with reliable reproducibility. Subsequent
iterations of crystallization trials focused on additional crystallization parameters
including volume ratio, drop dehydration, temperature, small molecule additives, etc.
Wizard I #10 and MCSG II #80 conditions contained similar components, and the final
best condition was obtained by combining shared components into a single new
condition. The optimal crystal condition was selected by varying molecular weight and
concentration of PEG. Subsequent additive screening identified sodium iodide as a
suitable ionic species able to positively modulate crystal packing and growth. With
sodium iodide incorporated into the crystallization condition, X-ray diffraction data
quality improved to <8Å resolution (Appendix 7). Unfortunately, X-ray diffraction data
collected from this crystal could not be properly scaled and/or integrated, indicating that
the crystal lattice was not perfectly aligned. Therefore, further modifications and
optimizations were required to overcome this limitation.
Initial attempts to replicate crystals obtained from MCSG I #95 using the composition
tables provided by the manufacturer were unsuccessful likely due to alteration in
chemical composition as a result of prolonged storage. By varying individual components
within the initial condition, crystals were reproduced; albeit, with lower concentration of
lower molecular mass PEG. This observation spawned further rounds of component
optimization involving individual component variation, DNA ratio, and further additive
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screening. Ultimately, crystals were generated that diffracted ~5.3Å resolution. Thus, by
careful, systematic optimization two initial lead crystallization conditions were
substantially improved into a single condition that resulted in full X-ray diffraction data
collection (Figure 23 and 24). The optimized Ku70-DNA crystal occupied a similar sized
unit cell compared to prior crystals of Ku70/80-DNA complex (Table 5), but crystallized
in a different space group. Although X-ray diffraction data obtained from optimized
crystals was able to be scaled and integrated, attempts at solving the structure by
molecular replacement failed, perhaps due to conformational changes within the Ku70
structure. Further attempts to obtain phase information could incorporate selenomethionine SAD phasing strategies.
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Figure 23. Progression of Ku70-loop16 crystal morphology through iterations of
optimization. The initial hit from MCSG I #95 (left) was optimized through lowering the
concentration and molecular weight of the PEG in the crystallization condition. This was
followed by raising the DNA-to-protein ratio, and performing additive screening, which
ultimately resulted in the optimized crystal (right). Each stage of crystal optimization
yielded improvement in crystal growth shape, size, and X-ray diffraction data quality.

Figure 24. Progression of Ku70-DNA crystal X-ray diffraction data quality.
Comparison of improvement in both diffraction intensity and resolution of data correlated
with the improvement in crystal size and morphology, with (A) the initial hit and (B) the
optimized crystal.
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Table 4. Optimization of MCSG I #95 for Ku70-loop16. The list is sectioned by the
order of optimization focus, each varying one aspect of the crystallization environment.
Resolution is the average of multiple crystals examined by X-ray diffraction. The bolded
condition is carried forward as the base condition for the next round of optimization.
Condition variance

X-ray screening result
(Resolution)

Additive with 0.1M Praseodymium(III) acetate hydrate

Non-diffracting
crystal/Salt

Additive with 0.1M Praseodymium(III) acetate hydrate and

Salt

0.05M ammonium sulphate
Lower PEG to 12% PEG2000

Protein (13Å)

Lower PEG to 12% PEG3350

Protein (15Å)

Lower PEG to 15% PEG1000

Protein (19Å)

DNA ratio increase from 1:1.2 to 1:1.5

Protein (8Å)

DNA ratio increase from 1:1.2 to 1:3

Protein (20Å)

5% v/v Ethyl acetate as additive

Protein (~5.3Å)

Table 5. Comparison of Ku70-DNA and Ku70/80-DNA crystal parameters.
Crystal

Unit cell lengths

Unit cell angles

Space group

(a, b, c) (Å)

(α, β, γ) (°)

Ku70-DNA (5.3Å)

115.92, 115.92, 141.07

90, 90, 120

P6 122

1JEY (2.5Å)

91.07, 91.07, 152.84

90, 90, 90

P212121
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3.8 Crystallization of Ku70-DNA-PAXX Generated PAXX
Crystals
Initial crystallization hits obtained from sparse matrix screening of Ku70-DNA-PAXX
complex resulted in microcrystals that were determined to be composed of protein rather
than salt using X-ray diffraction scanning (Figure 25, Appendix 8). Initial hits were
optimized for increased crystal size using additive screening and volume ratio variation.
Optimization generated numerous, well-shaped crystals (Figure 26 and 27, Table 6) that
diffracted to relatively high resolution (~5.3Å). Unexpectedly, when X-ray diffraction
data was collected and analysed for these crystals, the unit cell parameters were found to
be too small to contain a complete Ku70-DNA-PAXX complex within the asymmetric
unit. Furthermore, the space group was found to be very similar to that of truncated
PAXX from PDB 3WTF (Table 7), suggesting that PAXX alone had crystallized under
the conditions used. This suggests that while EMSA analysis showed that PAXX could
supershift a Ku-DNA complex (74), in crystallization trials, PAXX was dissociated from
Ku70-DNA complex. In the supersaturated state, PAXX crystallization was apparently
favoured over its interaction with the Ku70-DNA complex in less concentrated
conditions. Nevertheless, since the conditions used for full length PAXX crystallization
were different from those used to determine the structure of the N-terminal PAXX
domain (PDB 3WTF), X-ray data was collected and the structure determined by
molecular replacement. The resulting model of PAXX was refined and compared to the
deposited structure (see section 3.9). Due to the high propensity of PAXX for
crystallization, later trials to obtain crystals of Ku70-DNA-PAXX were performed using
longer DNA substrates that enhance interaction of Ku70-DNA and PAXX. At the point
of completing this thesis no promising conditions had been identified for Ku70-DNAPAXX complex using any of the DNA substrates tested.
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Figure 25. Initial hit of Ku70-DNA-PAXX complex. Similar microcrystals were
obtained from several conditions. All crystals exhibited a 3D hexagonal shape with welldefined edges and faces. Image quality was limited by the magnification power of the
microscope and mounted imaging system.

Figure 26. Images of PAXX crystals in two different crystallization conditions. For
complex mixtures of Ku70-DNA-PAXX, Ku70 and the DNA substrate were mixed in a
molar ratio of 1:1.5, then PAXX was added in equimolar ratio to Ku70. (A) shows the
typical hexagonal crystal morphology from Ku70-DNA-PAXX sample with mother
liquor containing 0.1M Bis-Tris Propane pH7, 1M ammonium citrate tribasic pH7. (B)
Optimized PAXX crystals used for data collection diffracted to 3-3.5Å resolution.
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Table 6. Summary of PAXX Crystallization and X-ray diffraction. Crystals of
sufficient size were screened using X-ray diffraction and the crystal contents were
identified. The bolded condition yielded the best initial hit for subsequent optimization by
equilibrating with 1.1M ammonium acetate instead of the usual 1.5M.
Crystallization condition

DNA
substrate

Crystal identity
(Resolution)

0.02M calcium chloride, 0.1M sodium acetate pH4.6, 30%
v/v MPD

Loop16

Salt

0.1M sodium chloride, 0.1M Bis-Tris pH6.5, 1.5M
Ammonium Sulphate, 0.1M Strontium chloride
hexahydrate

Loop16

Salt

0.2M magnesium chloride, 0.1M HEPES pH7.5, 30% v/v
PPG P400

Loop16

Salt

0.2M magnesium chloride, 20% w/v PEG3350

Loop16

Salt

0.2M lithium acetate, 20% w/v PEG3350

Loop16

Protein (25Å)

0.1M HEPES pH7.5, 10% w/v PEG8000, 8% v/v ethylene
glycol

Loop16

Protein (19Å)

1M lithium chloride, 30% w/v PEG6000, 0.1M sodium
acetate

Loop16

Protein (15Å)

0.1M Tris pH8.5, 1.4M ammonium tartrate dibasic

Loop16

Protein (10Å)

0.1M Bis-Tris Propane pH7, 1M ammonium citrate
tribasic pH7

Loop16

Protein (5.5Å)

Optimized with lower dehydration and longer time

Loop16

Protein (33.5Å)

0.2M potassium acetate pH4.5, PEG 400, 550 MME, 600,

14b10T

Non-diffracting
crystal

14b10T

Non-diffracting
crystal

1K, 2K, 3350, 4K, 5K MME, 6K, 8K and 10K
20% v/v 2-Propanol, 0.1 M MES monohydrate pH 6.0,
20% w/v PEG2000
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Figure 27. Single image of X-ray diffraction pattern from PAXX data collection. Xray diffraction data reached 3.5Å resolution. The experimentally indexed space group and
unit cell closely resembles that of PDB 3WTF (Table 7), suggesting the crystal unit cell
contained a single PAXX homodimer.

Table 7. Comparison of experimental and referenced PAXX crystal parameters. The
unit cell parameters and space group determined are listed.
Crystal

Unit cell lengths

Unit cell angles

Space group

(a, b, c) (Å)

(α, β, γ) (°)

PAXX (3Å)

90.99, 90.99, 152.82

90, 90, 120

P6 122

PAXX (3.5Å)

91.07, 91.07, 152.84

90, 90, 120

P6 122

3WTF (3.45Å)

91.95, 91.95, 153.2

β=120

P6 522
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3.9 PAXX Structure Determined from Full-length PAXX
X-ray diffraction data from crystals of full-length PAXX were collected to 3.5Å at the
Advanced Photo Source Synchrotron, Argonne National Labs. The structure of fulllength PAXX was determined by molecular replacement using the N-terminal domain of
PAXX as the search model (PDB 3WTF). The final model was refined to R work and Rfree
values of ~0.26 and ~0.30, respectively (Figure 28, Table 7). Comparison of the fulllength structure of PAXX to the N-terminal domain of PAXX (3WTF) showed very little
difference with both containing a 7-stranded antiparallel beta-sandwich with a helix-turnhelix motif inserted between strands 4 and 5. As well, both had almost identical amounts
of coverage for the extended C-terminal helices that forms the dimerization domain and
extends away from the N-terminal head domain. The fact that both structures were
similar despite the current structure containing full-length protein, suggests that the Cterminal region of PAXX remains highly flexible in the absence of DNA and/or Ku70.
The full-length structure did however, contain some additional coverage compared to the
N-terminal structure of PAXX. Interestingly, the determined PAXX structure contains an
additional β-strand (residues L185 – F190) that could be modelled into electron density
(Figure 28B). This β-strand stacked adjacent to the outer β-sheet in an anti-parallel
arrangement extending the sheet from 3 to 4 strands (Figure 28C). The presence of the Cterminal strand not only indicates that our structure contained full-length protein, but also
represents the first evidence that PAXX C-terminal tails fold back to interact with the
head domain. This finding is of particular interest since the C-terminal region is known to
mediate both DNA and Ku70 interaction. As well, the C-terminus strand folding back to
the N-terminal head domain mirrors the structure of XLF, further extending the similarity
between these two related NHEJ repair proteins. The presence of additional density in our
structure also excludes the possibility that the C-terminus of PAXX was truncated during
the crystallization process. Overall, the structure of full-length PAXX recapitulated the
features of a previously deposited PAXX N-terminal domain structure, and unveiled
additional information about the general structure of PAXX.
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Figure 28. Highlighted Structural Information of PAXX. (A) An additional -strand was
solved using the experimental data, highlighted in green. The N-terminus, secondary
structures, and the C-terminal amino acids are denoted. (B) The electron density map is
illustrated showing the modelled -strand structure fitted in an anti-parallel orientation
stacking with the outer -sheet at the N-terminal head domain of PAXX. (C) The same
region without the electron density map. The figures are rendered using PyMOL.
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Chapter 4

4

Discussion

Through the efforts in this study, protein yield no longer limits structural studies of NHEJ
assemblies. The methods developed here, therefore, provide the grounds upon which
future functional characterization and complementary structural analysis can proceed.
Such investigation will greatly increase insight into the molecular mechanisms of NHEJ
DNA repair and permit effective targeting of this pathway for cancer treatment. Using
advances made in protein production, several NHEJ assemblies were chosen for further
structural studies.
LX4-XLF-DNA represents the ‘holy grail’ for structural characterization of NHEJ
assemblies due to its essential role in mammalian DNA DSB repair. This assembly
represents the final ligation complex that completes repair by coordinating re-joining of
DNA ends at a DSB site. As a DSB site includes two broken strands, current models
speculate that two LX4 complexes participate in repair; however, how LX4 interacts with
DNA and carries out ligation is currently unknown (70, 95). Understanding the molecular
mechanism driving the ligation complex assembly is vital for clarifying how the complex
coordinates DSB repair. Importantly, knowledge of LX4 and related NHEJ complexes
may lead to new avenues for chemotherapeutic intervention.
Given recent reports that Ku70 and Ku80 seem to have discrete functions independent of
their heterodimeric assembly, understanding how these proteins form complexes on their
own with DNA, and binding factors such as PAXX, becomes of great interest. In
particular, the Ku70-DNA-PAXX complex is poorly characterized and warrants further
investigation. Crystallization of such complexes provides an obvious route for elucidating
structure required for understanding molecular mechanism; however, large multicomponent assemblies are challenging targets for crystallization given the multitude of
factors influencing crystal growth and quality. Work in this thesis focused on pursuit of
both LX4- and Ku70-based complexes. Numerous conditions were identified that gave
rise to crystals that were of no value (i.e. non-diffracting, unable to be optimized, and/or
salt). Nevertheless, by exploring many conditions, microcrystals were identified that
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could be optimized. Through careful observation and systematic optimization, a PAXX
homodimer structure was solved and refined at 3Å resolution. This structure validated the
idea that the C-terminal region of PAXX is highly flexible in the absence of Ku70 and/or
DNA, and that at least a small portion of the C-terminal tail folds back to interact with the
N-terminal head domain as has been observed for XLF. In addition, two promising
conditions were identified for crystallization of Ku70-DNA, with one that permitted Xray diffraction data to be collected up to 5.3Å resolution. Ultimately, significant progress
has been made towards elucidating higher-order structures of NHEJ factors. Based on
these findings, further optimization, combined with complementary structural techniques,
are expected to permit structural determination of several new NHEJ assemblies.

4.1 Overcoming Practical Limits to Studying NHEJ
Complex Structures
The preferred expression system for generating protein for X-ray crystallographic studies
is indisputably bacterial. This reflects the ease of use, low cost and potential for high
yield. Not surprisingly, the vast majority of structures deposited in the protein data bank
were determined from protein generated with bacterial expression systems.
Unfortunately, many proteins are not able to be easily expressed in bacteria due to
problems associated with low expression, degradation and/or solubility. Heterologous
gene expression often fails due to codon-bias, lack of necessary post-translational
modifications, missing prosthetic groups, unavailable chaperones, etc. Some of these
limitations have been successfully overcome by codon-optimization, use of bacterial
strains with altered properties, variation in cell growth temperature and levels of
induction, changes in promoters, addition of fusions and altering domain boundaries of
target proteins. Currently, determining which (if any) of these approaches result in
desirable outcomes must be determined empirically.
In this thesis, the expression and purification of several core NHEJ factors was
significantly improved. Guided by empirical evidence, numerous alterations were
explored to improve protein yield and purity. Although not discussed in depth, a variety
of bacterial strains, induction times, IPTG concentrations and temperatures were
evaluated for their impact on expression efficiency and solubility for each protein of
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interest. In addition to these considerations, other parameters (buffer components,
chromatographic techniques) were explored to maximize yield and purity of the final
product. Perhaps the largest gains came from a combination of codon optimization and
re-engineering of construct design. For LX4, the use of a dual co-expression vector was
particularly important for increasing the overall levels of Ligase IV expression. Ligase IV
is not stable in the absence of XRCC4 and therefore having both proteins co-expressed at
similar levels ensured maximal recovery of complex. LX4 purity was improved
dramatically, simply by extending the His tag from 6 to 9 residues and moving the
placement of the tag to the N-terminus of Ligase IV (the limiting component of LX4).
Overall, LX4 expression and purification was significantly improved using the newly
synthesized construct, with a >10-fold increase in final yield compared to earlier
expression strategies. The resulting protein was stable to >15 mg/ml and highly active for
intermolecular ligation.
Whether the approaches used to improve LX4 yield will be generally transferrable for
heterologous expression of other complexes remains unclear. All of the parameters that
were modified for LX4 expression and purification have been reported for other systems.
Unfortunately, at this point it is not possible to say with certainty if any particular
parameter will result in desired outcomes. However, based on the findings for LX4, and
also Ku70/80, it seems that codon optimization, selection of domain boundaries, and
placement of purification/solubility fusions are particularly important factors for
improving protein yield.
In order to understand the molecular mechanism of NHEJ it is essential to determine
structures of higher-order assemblies in the presence of DNA. Thus, an important
consideration in crystallographic studies involving NHEJ factors is not just protein, but
also DNA. The challenge with nucleoprotein complexes is that the DNA component
plays a critical role in crystal lattice packing that can be very difficult to optimize.
Frequently, crystals of protein-DNA complexes diffract poorly until an optimal DNA
substrate can be determined. For NHEJ studies the consideration is further complicated
by the need to stabilize large complexes in a monodisperse state that is essential for
crystallization to occur. NHEJ is not DNA sequence-dependent. As such, designing DNA
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substrates that remain bound to protein in only one state is challenging. For complexes of
Ku70, limiting diffusion along DNA was addressed by use of a stem-loop structure on
one end of the substrate. Although the stem-loop with an optimal length of 16bp seemed
to work reasonably well for Ku70, more work needs to be done to explore variation in the
stem-loop structure itself and perhaps the type of ends (blunt, overlap, etc.). For
complexes of LX4, optimization of DNA substrates is critical. Although several attempts
were made here to use substrates that would ‘stall’ LX4 activity at a given step in
ligation, the overall success was very limited. It will be important to try different DNA
substrates that employ variation in length and end-compatibility. Now that ample
amounts of LX4, XLF, PAXX, Ku70/80, and Ku70 are readily available, it will be
feasible to screen a large variety of DNA substrates for structure determination of various
NHEJ assemblies.

4.2 Crystallographic Strategies to Facilitate High Quality
Diffraction Data
Crystallography represents the most successful method for determining structures of
biological macromolecules, with ~90% of all PDB deposited structures determined by Xray crystallography. Nevertheless, challenges in obtaining well-ordered crystals are
frequently encountered. To improve success in obtaining suitable crystals for high
resolution data collection, it is important to understand and fully exploit the basic
principles of crystal growth.
Two major events are required for obtaining crystals: supersaturation and nucleation.
Under supersaturating conditions, solutes (proteins) in solution start to self-associate.
When a cluster of well-ordered solute molecules reaches a critical size, nucleation of the
crystal can occur. Nucleation is energetically unfavourable and considered the limiting,
black-box step in crystal formation. Once nucleation occurs, sustained supersaturation of
protein is sufficient to drive crystal growth (Figure 29). Despite the principles of
crystallization being the same for all solutes, macromolecules present significant
challenges compared to their smaller molecule counterparts. In particular,
macromolecular crystallography must ensure that the protein is able to remain stable (i.e.
toward degradation, oxidation, unfolding and aggregation) over the conditions (time,
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temperature, concentration) required to achieve supersaturation. Practically, this requires
empirically determining proper conditions (ionic strength, pH, temperature, etc.). During
sparse matrix screening, which samples reagent formulations that have previously
crystallized a protein and permits rapid and economical coverage of successful
crystallization space, many of these parameters are systematically explored and therefore,
it is unlikely that simply screening more crystallization conditions would be fruitful once
several thousand conditions have been evaluated.
As in the case of Ku70-DNA, once conditions are found that promote stability during
supersaturation, crystal hits tend to occur frequently. Instead of further screening for new
crystallization conditions, which is unlikely to improve crystal quality, small alterations
of individual components in a crystallization condition, small changes to domain
boundaries to remove flexible regions and/or changes in the rate and extent of
supersaturation and nucleation through micro-seeding, etc. are likely to result in better
crystal growth.
Moving forward, it would seem most appropriate to investigate altered DNA structures in
combination with micro-seeding and perhaps different methods of crystallization
(anaerobic conditions, microbatch and free interface diffusion) other than hanging drop
vapour diffusion to help improve diffraction quality of Ku70-DNA crystals.
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Figure 29. Idealized states of solutes. The curves separating the unsaturated,
supersaturated and precipitation zones are idealized for illustration of concept. In the
hanging drop crystallization method, the volume of the drop continues to decrease,
leading the state of the protein and precipitant to rise, crossing into the supersaturated
nucleation zone. Once nucleation occurs, the effective protein concentration will decrease
as more protein arranges into the crystal rather than remaining dispersed in the solvent.
Meanwhile, precipitant concentration continues to increase as the drop becomes
dehydrated by equilibration with the reservoir solution (illustrated by the state shift of the
orange dot). Hence, careful control of the rate and extent of dehydration allows the state
of the solute to linger within the supersaturated crystal growth zone, facilitating protein
crystallization to suitable size for X-ray diffraction.

79

4.3 Methods to Complement Crystal Structure
Determination
Current technical limitations prevent visualization of protein interactions at the atomic
level in real-time, resulting in a disconnect between functional and mechanistic
understanding. Although X-ray crystallography permits visualization of snapshots of
proteins and other macromolecules, this is only achieved within a static, crystalline state.
There are numerous techniques that can be employed for structural characterization and
interaction of proteins. Nuclear magnetic resonance spectroscopy (NMR) has been
extensively used for structure determination of small-to-medium sized proteins in
solution. Unfortunately, the sample criteria for NMR is relatively stringent and its use for
further studies of larger NHEJ assemblies with DNA is likely to be limited. Similarly,
hydrogen-deuterium exchange (HDX) can be a great complement to X-ray
crystallography and NMR studies (169). However, this requires prior assignment of the
spectrum for the protein which may not be available and, considering the size of the core
components in a LX4 complex (DNA Ligase IV, ~104kDa) or Ku70-DNA-PAXX
(~70kDa), obtaining the spectrum may not be feasible. Mass spectrometry provides an
alternative detection method with much fewer restraints and higher capacity to analyse
complexes (170); however, spatial resolution is very poor and data interpretation is
frequently very difficult.
SAXS is another emerging, complementary method for characterizing complexes. This
method enables investigation of large complexes in solution, bypassing the experimental
bottleneck of crystallization; however, the degree of resolution is still very poor. SAXS is
incredibly informative for determining the size, shape and distribution of proteins within
a sample. As well, shape differences due to complex formation can be determined to infer
conformational changes within proteins. Although on its own, SAXS is not overly wellsuited to understand molecular structures, it can be useful when combined with other
techniques such as X-ray crystallography. SAXS information would greatly assist in the
overall understanding of protein-protein and protein-DNA interaction pertaining to LX4
and PAXX complexes, in particular, revealing the overall assembly of LX4 complexes
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around the DNA ends, and the conformational changes that allows PAXX to bind KuDNA complexes.
The use of cryo-EM has recently received renewed attention due to improved detectors
that have resulted in the ability to determine structures of large macromolecular
assemblies at near atomic resolution. Unlike NMR, cryo-EM is not limited by sample
size. In addition, unlike crystallography, there is no requirement for crystal growth and
samples can be imaged in solution in a variety of dynamic states. Cryo-EM allows studies
of protein complexes that resist crystallization due to surface flexibility and/or sample
heterogeneity due to dynamic intermolecular interactions (171). Cryo-EM imaging can
resolve the general structure of protein complexes of over 100kDa, which is the case for
both LX4-XLF-DNA and Ku70-DNA-PAXX. Importantly, cryo-EM can provide spatial
details about protein complexes, and has the potential to resolve structure at resolutions
that rival X-ray crystallography (172). With crystal structures available for domains and
truncated complexes of NHEJ proteins, one could use available structures to fit density
maps generated through cryo-EM and thereby provide structural insight into larger more
dynamic complexes. Given these advantages and the development of modern detectors
and image processing capacities, cryo-EM seems perfectly suited for future use in
studying large NHEJ assemblies.

4.4 Implications for NHEJ Complex Interactions
Although some structural information is available for domains of DNA Ligase IV and
segments of XRCC4 and XLF, their molecular mechanism of action in NHEJ DNA repair
has yet to be determined. Models of the ligation complex have been suggested based on
functional studies, however, these remain highly speculative and further structural studies
involving higher-order assemblies with DNA are required.
Work reported here for Ku70 suggests that it forms a stable homodimer in the absence of
Ku80. This is particularly interesting since recent studies suggest that Ku70 and Ku80
may function independent of a heterodimer. Our finding that Ku70 forms a stable
homodimer agrees with these reports and suggests that Ku80 may also be able to form
homodimers. As well, analysis of Ku70 demonstrates its ability to bind DNA at similar
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levels to Ku70/80 heterodimer and also interact with PAXX (74). These findings clearly
suggest that Ku70 alone can function in the absence of Ku80 and supports findings from
prior reports.
Previous studies of Ku70 in Bax-mediated apoptosis have shown a Ku70-dependent
competitive interaction with Bax and cyclin E under genotoxic stress (173). Further
studies demonstrated that phosphorylation of Ku70, through interaction with cyclin B1Cdk1 and A2-Cdk2, caused dissociation of the Ku70/80 dimer. This type of structural
alteration may reduce participation of Ku70 in DSB repair during S and M phase and
allow HR to occur in a cell cycle-dependent manner (174, 175). The finding that Ku70Bax interaction results in regulated interaction outside the nucleus, potentially uncovering
a role of Ku70 in controlling cellular processes related to genome stability, raises many
questions (176–178). Importantly, post-translation modification observed in this study
demonstrates a means of regulating participation of Ku70 in hetero- and homodimer
formation.
The lack of robust evidence for Ku70 functioning outside of a Ku70/80 heterodimer may
be due to the strong phenotype Ku70/80 have in NHEJ, as well as limitations in
methodological approaches. For instance, recent studies have shown that previous studies
overlooked the Ku70/80 RNA binding effect, leading to potential bias in interpreted
results since a sizable amount of Ku70 and Ku80 would not have been released to the
soluble fraction during sample extraction (50). Further studies are needed to address
whether Ku70 can carry out functions, such as its interaction with PAXX, in the absence
of Ku80 in vivo.
Although our structure of the full-length PAXX only provided new information for a
portion of the C-terminal region, observing that a part of the C-terminal region interacts
with the head domain strengthens the parallel between PAXX and XLF. The fact that
most of the C-terminal region of PAXX remains disordered, further suggests that it may
only become ordered during interaction with Ku70 and DNA. PAXX has been shown to
have some redundancy with XLF, which is not surprising given their structural similarity.
XLF likely occupies the space required for PAXX interaction with Ku. Since XLF has
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additional interactions with XRCC4 and LX4 through its C-terminal tail, that do not
appear to be shared with PAXX, it may be that PAXX is only required as a backup when
XLF fails to function (179). Structural studies of Ku-DNA-PAXX and Ku-DNA-XLF
will be essential for addressing these possibilities.

4.5 Outstanding Questions for NHEJ in Cancer Treatment
One of the best-established hallmarks of cancer is genomic instability due to loss of DNA
repair. In many types of cancer, HR is inactivated through mutation of repair factors such
as BRCA1 and BRCA2 (180, 181). In this case, tumour cells become particularly reliant
on NHEJ, making NHEJ an attractive pathway for therapeutic intervention. Simultaneous
inhibition of NHEJ and treatment with clastogenic agents can greatly favour elimination
of tumour cells. Similar strategies (involving PARP1 inhibition in BRCA2 deficient
tumour cells) have already shown great promise (180, 182, 183). Therefore, molecular
understanding of the NHEJ pathway is critical for further efforts to develop adjuvant
cancer therapy targeting the NHEJ repair pathway.
Previous efforts to determine structures of proteins involved in NHEJ have been largely
limited to domains or individual proteins. Moving forward, what will be required for both
mechanistic understanding and the ability to effectively target the repair pathway is highresolution structural information for larger NHEJ assemblies. In particular, the general
assembly of LX4 around DSB ends in coordination with Ku and other factors has never
been observed, hindering our progress of understanding the molecular mechanisms of
NHEJ. With the discovery of PAXX, structural complex of PAXX and Ku can reveal
important characteristics that allows Ku to interact with multiple targets and coordinate
repair efforts. Much of the functional outcome of altering factor participation in repair
has been explored, but how does these factors achieve those specific outcomes? What is
the molecular mechanisms driving their interactions? And perhaps more importantly for
understanding pathological states, how does the absence of a factor impact the overall
repair? Given the recent advances in cryo-EM, such efforts are likely to benefit greatly
from a combined approach incorporating both X-ray crystallography and cryo-EM.
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Appendices
Appendix 1. List of oligonucleotides. Oligonucleotides synthesized and utilized for
crystallography are listed here.
Oligonucleotide Sequence (5’-3’)
Loop14-1
Loop15-1
Loop16-1
Loop17-1
Loop18-1
Loop19-1
Loop34-1

CGCGCCCAGCTTTCCCAGCTAATAAACTAAAAAC
CGCGCCCAGCTTTCCCAGCTAATAAACTAAAAACC
CGCGCCCAGCTTTCCCAGCTAATAAACTAAAAACCC
CGCGCCCAGCTTTCCCAGCTAATAAACTAAAAACCCC
CGCGCCCAGCTTTCCCAGCTAATAAACTAAAAACCCGC
CGCGCCCAGCTTTCCCAGCTAATAAACTAAAAACCCGGC
CGCGCCCAGCTTTCCCAGCTAATAAACTAAAAACCCAATAAACTAAAAA
CCCCC

Loop14-2
Loop15-2
Loop16-2
Loop17-2
Loop18-2
Loop19-2
Loop34-2

GTTTTTAGTTTATTGGGCGCG
GGTTTTTAGTTTATTGGGCGCG
GGGTTTTTAGTTTATTGGGCGCG
GGGGTTTTTAGTTTATTGGGCGCG
GCGGGTTTTTAGTTTATTGGGCGCG
GCCGGGTTTTTAGTTTATTGGGCGCG
GGGGGTTTTTAGTTTATTGGGTTTTTAGTTTATTGGGCGCG

Y7-1
Y7-2
Y7-3

TTTATTACCTCCCCTACCCAC
GTGGGTAGGGGAGGATTGTTT
AAACAATTAATAAA

TS1
TS2
TS3

GATCCCTCTAGATAT
CGGGCCCTCGATCCG
CGGATCGAGGGCCCGATATCTAGAGGGATC

14b1T
14b2T
14b3T
14b4T
14b5T
14b10T
14bottom

TGGGCTGGTCGGGTT
TGGGCTGGTCGGGTTT
TGGGCTGGTCGGGTTTT
TGGGCTGGTCGGGTTTTT
TGGGCTGGTCGGGTTTTTT
TGGGCTGGTCGGGTTTTTTTTTTT
ACCCGACCAGCCCA

KP1530b

CGCGAGCTTTCCCAGCTGATCCCTCTAGATAT
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KP1630b
KP1730b

CGCGAGCTTTCCCAGCTGATCCCTCTAGATATC
CGCGAGCTTTCCCAGCTGATCCCTCTAGATATCA

18stall-1
18stall-2
18stall-3

TGATGCGTc (3’ dideoxycytosine)
(5’ phosphate) GTCAGGCTG
CAGCCTGACGACGCATCA

stack9-1
stack9-2

ATGATTAGAACGGACACTGGATTGTGACCT
TCTAATCATAGGTCACAATCCAGTGTCCGT

102

Appendix 2. Structure of annealed DNA substrates.
Name

Component

Loop14

Loop14-1 &
loop14-2

Loop15

Loop15-1 &
loop15-2

Loop15/16

Loop15-1 &
loop16-2

Loop15/17

Loop15-1 &
loop17-2

Loop16

Loop16-1 &
loop16-2

Illustrated Structure
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Loop16/15

Loop16-1 &
loop15-2

Loop17

Loop17-1 &
loop17-2

Loop17/15

Loop17-1 &
loop15-2

Loop18

Loop18-1 &
loop18-2

Loop19

Loop19-1 &
loop19-2

Y7

Y7-1 & Y7-2
& Y7-3

TS

TS1 & TS2
& TS3
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14b1Tail

14b1T &
14bottom

14b2Tail

14b1T &
14bottom

14b3Tail

14b1T &
14bottom

14b4Tail

14b1T &
14bottom

14b5Tail

14b1T &
14bottom

14b10Tail

14b1T &
14bottom

KP1530

Loop15 &
KP1530b

KP1630

Loop16 &
KP1630b

KP1730

Loop17 &
KP1730b
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18stall

18stall-1,
18stall-2, &
18stall-3

Stack9

Stack9-1 &
stack9-2
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Appendix 3. Comparison of XLF expression and purification using different methods.
Lane 1 shows the Trident Prestained Protein Ladder (GeneTex); lane 2 shows XLF
expressed in E. coli BL21 (DE3) and purified using the method indicated in Chapter
2.2.2, but using MonoQ in place of Heparin column; lane 3 shows XLF expressed in E.
coli Rosetta™(DE3)pLysS and purified using the same method as lane 1; lane 4 shows
XLF expressed in E. coli Rosetta™(DE3)pLysS, and purified using Heparin column as
the second chromatography method.
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Appendix 4. Ku70-DNA bound in solution. The complex formation of Ku70 and
loop16 was evaluated with size-exclusion chromatography using similar procedure to
Chapter 2.6 with a dual-detection fast protein liquid chromatography system. The red line
indicates absorbance at 230nm, the blue line indicates absorbance at 280nm. DNA and
Ku70 were both detected by gel electrophoresis of fractionated samples, indicating
interaction.
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Appendix 5. List of crystallization conditions for Ku70 and X-ray screening
outcomes.
Crystallization condition

X-ray screening result

0.2M potassium sulphate, 20% w/v PEG 3350

Salt

0.2M potassium formate pH7.3, 20% w/v PEG3350

Salt

0.2M potassium acetate, 20% w/v PEG3350

Salt

1M NaH2PO4/K2HPO4 pH6.9

Salt

24% w/v PEG 1500, 20% v/v glycerol

Salt

0.2M Lithium sulphate, 0.1M Sodium phosphate dibasic

Salt

pH4.2, 10% v/v 2-propanol
1M Potassium sodium tartrate, 0.1M Imidazole pH8, 0.2M

Salt

Sodium chloride
0.1M Bis-Tris pH5.5, 25% w/v PEG3350

Non-diffracting crystal

0.2M Calcium acetate, 0.1M Imidazole pH8, 20% w/v

Non-diffracting crystal

PEG1000
0.2M Calcium acetate, 0.1M Imidazole pH8, 10% w/v

Non-diffracting crystal

PEG8000
0.2M Lithium sulphate, 0.1M Tris pH7, 1M Potassium

Non-diffracting crystal

sodium tartrate
0.8M potassium sodium tartrate, 0.1M Tris pH8.5, 0.5% w/v

Non-diffracting crystal

PEG5000 MME
Condition above with 0.1M Strontium chloride hexahydrate

Salt
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Appendix 6. List of crystallization conditions for Ku70-DNA and X-ray screening
outcomes. The three bolded conditions underwent extensive optimization varying
multiple different components for crystallization.
Crystallizing condition
0.15M DL-Malic Acid pH 7, 20% w/v PEG3350

DNA
substrate
Loop14

Loop14

X-ray screening
result (Resolution)
Non-diffracting
crystal
Non-diffracting
crystal
Non-diffracting
crystal
Non-diffracting
crystal
Protein (15Å)

Loop14

Salt

Loop16

Loop16

Non-diffracting
crystal
Non-diffracting
crystal
Non-diffracting
crystal
Non-diffracting
crystal
Protein (15Å)

Loop16
Loop16
Loop16

Protein (20Å)
Protein (20Å)
Salt

Loop16

Salt

Loop16

Salt

Loop16
Loop16

Salt
Salt

Loop16

Salt

Loop16

Salt

Loop16

Salt

0.2M magnesium chloride, 0.1M sodium citrate
pH5.5, 40% v/v PEG400
0.2M sodium malonate pH7, 20% w/v PEG3350

Loop14

0.8M lithium chloride, 0.1M Tris pH8.5, 32% w/v
PEG4000
0.2M sodium chloride, 0.1M HEPES pH7.5, 25%
w/v PEG3350
1M lithium chloride, 30% w/v PEG6000, 0.1M
sodium acetate
0.1M Lithium sulphate monohydrate, 0.1M Sodium
citrate tribasic dihydrate pH5.5, 20% w/v PEG1000
0.2M ammonium formate pH6.6, 20% w/v PEG3350

Loop14

0.2M Ammonium sulphate, 0.1M BIS-TRIS pH6.5,
18% v/v PEG400
0.6M sodium chloride, 0.1M MES pH6.5, 20% w/v
PEG4000
0.2M sodium chloride, 0.1M HEPES pH7.5, 25%
w/v PEG3350
0.1M Tris pH7, 20% w/v PEG1000
0.1M Tris pH7, 20% w/v PEG2000 MME
0.2M calcium chloride, 0.1M Tris pH8.5, 25% w/v
PEG4000
0.2M magnesium chloride, 0.1M sodium citrate
pH5.5, 40% v/v PEG400
0.2M magnesium chloride, 0.1M Bis-Tris pH5.5,
25% w/v PEG3350
0.2M magnesium chloride, 20% w/v PEG3350
0.8M lithium chloride, 0.1M Tris pH8.5, 32% w/v
PEG4000
0.8M potassium sodium tartrate, 0.1M Tris pH8.5,
0.5% w/v PEG5000 MME
1M lithium chloride, 30% w/v PEG6000, 0.1M
sodium acetate
2.5M Sodium chloride, 0.1M Imidazole pH8, 0.2M
Zinc acetate

Loop14

Loop16
Loop16
Loop16
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3% w/v Dextran sulphate sodium salt, 0.1M BICINE
pH8.5, 15% w/v PEG20000
0.2M Magnesium acetate tetrahydrate, 20% w/v
PEG3350
0.2M Magnesium chloride, 20% w/v PEG3350
0.2M Potassium citrate tribasic monohydrate, 20%
w/v PEG3350
0.2M Potassium sulphate, 20% w/v PEG3350
0.2M Sodium acetate trihydrate, 20% w/v PEG3350
0.2M Zinc acetate dihydrate, 20% w/v PEG3350
0.2M Ammonium acetate, 0.1M Sodium citrate
tribasic dihydrate pH5.5, 24% v/v PEG400
4% v/v (+/-)-2-Methyl-2,4-pentanediol, 0.1M Citric
acid pH3.5, 20% w/v PEG1500

Loop16

Salt

Loop18

Salt

Loop18
Loop18

Salt
Salt

Loop18
Loop18
Loop18
Loop19

Salt
Salt
Salt
Non-diffracting
crystal
Non-diffracting
crystal

Loop19
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Appendix 7. Optimization of Wizard I #10 and MCSG II #80 for Ku70-loop16
crystal growth and X-ray diffraction.
Varying conditions
0.1M Tris pH7, 20% w/v PEG2000 MME; additive 1M
Sodium malonate pH7
0.1M Tris pH7, 20% w/v PEG2000 MME; additive 30% w/v
1,5-Diaminopentane dihydrochloride
0.1M Tris pH7, 20% w/v PEG1000; 0.2M sodium iodide
Further additive screen
0.16% w/v 3-Aminobenzenesulfonic acid, 5-Sulfosalicylic
acid dihydrate, p-Coumaric acid, PIPES, Terephthalic acid,
Vanillic acid mixture
0.2% w/v (±)-2-Methyl-2,4-pentanediol, 1,2,3-Heptanetriol,
Diethylenetriaminepentakis(methylphosphonic acid), DSorbitol, Glycerol mixture
0.2% w/v Barbituric acid, Betaine anhydrous, Phloroglucinol
Resorcinol, Tetrahydroxy-1,4-benzoquinone hydrate mixture
0.2% w/v 2,5-Pyridinedicarboxylic acid, Pyromellitic acid
Salicylic acid, trans-1,2-Cyclohexanedicarboxylic acid, transCinnamic acid mixture

Resolution
20Å
20Å
8Å

16Å
20Å
15Å
20Å
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Appendix 8. Ku70-DNA, Ku70-DNA-PAXX crystallization conditions. Listed are the
conditions that generated crystals. The first column indicates the name of the
crystallization kit where the condition was obtained; second column, salt identity and
concentration; third column, buffer identity, concentration and pH; fourth column,
percentage concentration by weight of PEG. None of the Ku70 crystals under these
conditions yielded diffraction data. Ku70-DNA and Ku70-DNA-PAXX crystals yielded
diffraction to varying degrees of resolution.
Ku70-DNA

Initial hits

MCSG I #95

0.2M sodium chloride 0.1M HEPES pH7.5

MCSG II #80
MCSG I #95
optimize 1
MCSG II #80
optimize 1
MCSG I #82

0.1M Tris pH7

20% w/v PEG2000

0.2M sodium iodide

20% w/v PEG1000

MCSG I #42

15% w/v PEG3350
0.1M Na2HPO4 pH4.2

40% w/v PEG300

0.1M Bis-Tris Propane
pH7
0.1M Tris pH8.5
0.1M HEPES pH7.5

1M ammonium
citrate tribasic pH7
1.4M ammonium
tartrate dibasic
25% w/v PEG3350

0.1M Tris pH8.5

20% w/v PEG4000

Initial hits

MCSG II #36

MCSG I #12

0.1M Tris pH7

0.2M magnesium
formate

MCSG III #31

MCSG I #9

20% w/v PEG1000

0.2M sodium chloride 0.1M HEPES pH7.5

MCSG II #83
PAXX

25% w/v PEG3350

0.2M magnesium
chloride
0.2M calcium
chloride

MCSG I #96

0.1M potassium
thiocyanate
0.2M lithium sulphate 0.1M HEPES pH7.5

1.4M sodium
malonate pH 7.0
1.5M Ammonium
Sulphate
30% w/v PEG2000
MME
25% w/v PEG3350

MCSG II #33

0.2M sodium fluoride

20% w/v PEG3350

MCSG I #44
MCSG I #72

0.1M Bis-Tris Propane
pH7
0.1M sodium chloride 0.1M Bis-Tris pH6.5
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